<article article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25867261</article-id><article-id pub-id-type="pmc">4402460</article-id><article-id pub-id-type="pii">bjc201593</article-id><article-id pub-id-type="doi">10.1038/bjc.2015.93</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial</article-title><alt-title alt-title-type="running">Bevacizumab combined with chemoradiotherapy</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Verstraete</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Debucquoy</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Dekervel</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>van Pelt</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Verslype</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Devos</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chiritescu</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Dumon</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>D'Hoore</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Gevaert</surname><given-names>O</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Sagaert</surname><given-names>X</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Van Cutsem</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Haustermans</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff8">8</xref></contrib><aff id="aff1"><label>1</label><institution>Laboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven</institution>, Leuven, <country>Belgium</country></aff><aff id="aff2"><label>2</label><institution>Laboratory of Hepatology, Department of Clinical and Experimental Medicine, University Hospitals Leuven, KU Leuven</institution>, Leuven, <country>Belgium</country></aff><aff id="aff3"><label>3</label><institution>Department of Digestive Oncology, University Hospitals Leuven, KU Leuven</institution>, Leuven, <country>Belgium</country></aff><aff id="aff4"><label>4</label><institution>Department of Abdominal Surgery, University Hospitals Leuven, KU Leuven</institution>, Leuven, <country>Belgium</country></aff><aff id="aff5"><label>5</label><institution>Laboratory of Cancer Data Fusion, KU Leuven</institution>, Leuven, <country>Belgium</country></aff><aff id="aff6"><label>6</label><institution>Stanford Center for Biomedical Informatics Research, Stanford University</institution>, Stanford, CA, <country>USA</country></aff><aff id="aff7"><label>7</label><institution>Department of Pathology, University Hospitals Leuven, KU Leuven</institution>, Leuven, <country>Belgium</country></aff><aff id="aff8"><label>8</label><institution>Radiation Oncology, University Hospitals Leuven &amp; Laboratory of Experimental Radiotherapy</institution>, Leuven, <country>Belgium</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>Annelies.debucquoy@med.kuleuven.be</email></corresp></author-notes><pub-date pub-type="ppub"><day>14</day><month>04</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>17</day><month>03</month><year>2015</year></pub-date><volume>112</volume><issue>8</issue><fpage>1314</fpage><lpage>1325</lpage><history><date date-type="received"><day>19</day><month>11</month><year>2014</year></date><date date-type="rev-recd"><day>04</day><month>12</month><year>2014</year></date><date date-type="accepted"><day>12</day><month>02</month><year>2015</year></date></history><permissions><copyright-statement>Copyright © 2015 Cancer Research UK</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Cancer Research UK</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/"><license-p>From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/</license-p></license></permissions><abstract><sec><title><offsets xml_i="5794" xml_f="5805" txt_i="11" txt_f="22">Background:</offsets></title><p><offsets xml_i="5816" xml_f="6000" txt_i="23" txt_f="207">This study characterises molecular effect of bevacizumab, and explores the relation of molecular and genetic markers with response to bevacizumab combined with chemoradiotherapy (CRT).</offsets></p></sec><sec><title><offsets xml_i="6022" xml_f="6030" txt_i="209" txt_f="217">Methods:</offsets></title><p><offsets xml_i="6041" xml_f="6376" txt_i="218" txt_f="553">From a subset of 59 patients of 84 rectal cancer patients included in a phase II study combining bevacizumab with CRT, tumour and blood samples were collected before and during treatment, offering the possibility to evaluate changes induced by one dose of bevacizumab. We performed cDNA microarrays, stains for CD31/CD34 combined with </offsets><italic><offsets xml_i="6384" xml_f="6385" txt_i="553" txt_f="554">α</offsets></italic><offsets xml_i="6394" xml_f="6564" txt_i="554" txt_f="724">-SMA and CA-IX, as well as enzyme-linked immunosorbent assay (ELISA) for circulating angiogenic proteins. Markers were related with the pathological response of patients.</offsets></p></sec><sec><title><offsets xml_i="6586" xml_f="6594" txt_i="726" txt_f="734">Results:</offsets></title><p><offsets xml_i="6605" xml_f="6941" txt_i="735" txt_f="1071">One dose of bevacizumab changed the expression of 14 genes and led to a significant decrease in microvessel density and in the proportion of pericyte-covered blood vessels, and a small but nonsignificant increase in hypoxia. Alterations in angiogenic processes after bevacizumab delivery were only detected in responding tumours. Lower </offsets><italic><offsets xml_i="6949" xml_f="6954" txt_i="1071" txt_f="1076">PDGFA</offsets></italic><offsets xml_i="6963" xml_f="7151" txt_i="1076" txt_f="1264"> expression and PDGF-BB levels, less pericyte-covered blood vessels and higher CA-IX expression were found after bevacizumab treatment only in patients with pathological complete response.</offsets></p></sec><sec><title><offsets xml_i="7173" xml_f="7185" txt_i="1266" txt_f="1278">Conclusions:</offsets></title><p><offsets xml_i="7196" xml_f="7271" txt_i="1279" txt_f="1354">We could not support the ‘normalization hypothesis' and suggest a role for </offsets><italic><offsets xml_i="7279" xml_f="7284" txt_i="1354" txt_f="1359">PDGFA</offsets></italic><offsets xml_i="7293" xml_f="7314" txt_i="1359" txt_f="1380">, PDGF-BB, CA-IX and </offsets><italic><offsets xml_i="7322" xml_f="7323" txt_i="1380" txt_f="1381">α</offsets></italic><offsets xml_i="7332" xml_f="7384" txt_i="1381" txt_f="1433">-SMA. Validation in larger patient groups is needed.</offsets></p></sec></abstract><kwd-group><kwd>bevacizumab</kwd><kwd>biomarkers</kwd><kwd>chemoradiotherapy</kwd><kwd>translational research</kwd><kwd>angiogenesis</kwd><kwd>rectal cancer</kwd></kwd-group></article-meta></front><body><p><offsets xml_i="7611" xml_f="7919" txt_i="1442" txt_f="1750">The standard treatment for patients with locally advanced rectal cancer (LARC) is chemoradiotherapy (CRT) followed by total mesorectal excision surgery. With this treatment still ∼30% of the patients will die within 5 years of completion of treatment due to the development of local and distant recurrences (</offsets><xref ref-type="bibr" rid="bib3"><offsets xml_i="7952" xml_f="7972" txt_i="1750" txt_f="1770">Aklilu and Eng, 2011</offsets></xref><offsets xml_i="7979" xml_f="8816" txt_i="1770" txt_f="2607">). To overcome this, an intensification of the preoperative treatment is urgently needed. One of the major factors of resistance to radiation therapy is hypoxia. Hypoxia in tumours is caused by an increase in diffusion distances with tumour expansion resulting in an inadequate supply of oxygen to cells at increasing distance from blood vessels (diffusion-related chronic hypoxia) or by chaotic vasculature and high interstitial pressures within tumours resulting in inadequate blood flow throughout the tumour (perfusion-related acute hypoxia). Anti-angiogenic treatments have been proposed to transiently normalise the tumour vasculature by pruning the immature vessels and by decreasing interstitial pressure, resulting in a transient increase in oxygenation and a window of opportunity for enhanced radioresponse and drug delivery (</offsets><xref ref-type="bibr" rid="bib66"><offsets xml_i="8850" xml_f="8859" txt_i="2607" txt_f="2616">Wildiers </offsets><italic><offsets xml_i="8867" xml_f="8872" txt_i="2616" txt_f="2621">et al</offsets></italic><offsets xml_i="8881" xml_f="8887" txt_i="2621" txt_f="2627">, 2003</offsets></xref><offsets xml_i="8894" xml_f="8896" txt_i="2627" txt_f="2629">; </offsets><xref ref-type="bibr" rid="bib60"><offsets xml_i="8930" xml_f="8935" txt_i="2629" txt_f="2634">Tong </offsets><italic><offsets xml_i="8943" xml_f="8948" txt_i="2634" txt_f="2639">et al</offsets></italic><offsets xml_i="8957" xml_f="8963" txt_i="2639" txt_f="2645">, 2004</offsets></xref><offsets xml_i="8970" xml_f="8972" txt_i="2645" txt_f="2647">; </offsets><xref ref-type="bibr" rid="bib72"><offsets xml_i="9006" xml_f="9014" txt_i="2647" txt_f="2655">Winkler </offsets><italic><offsets xml_i="9022" xml_f="9027" txt_i="2655" txt_f="2660">et al</offsets></italic><offsets xml_i="9036" xml_f="9042" txt_i="2660" txt_f="2666">, 2004</offsets></xref><offsets xml_i="9049" xml_f="9051" txt_i="2666" txt_f="2668">; </offsets><xref ref-type="bibr" rid="bib34"><offsets xml_i="9085" xml_f="9095" txt_i="2668" txt_f="2678">Jain, 2005</offsets></xref><offsets xml_i="9102" xml_f="9487" txt_i="2678" txt_f="3063">). Such combination of an anti-angiogenic agent and CRT could consequently be superior to individual treatment alone. Direct evidence was obtained in rectal cancer patients for the antivascular effect of bevacizumab (Avastin), a humanised monoclonal antibody to vascular endothelial growth factor (VEGF), which was the first angiogenesis inhibitor to be approved for cancer treatment (</offsets><xref ref-type="bibr" rid="bib67"><offsets xml_i="9521" xml_f="9529" txt_i="3063" txt_f="3071">Willett </offsets><italic><offsets xml_i="9537" xml_f="9542" txt_i="3071" txt_f="3076">et al</offsets></italic><offsets xml_i="9551" xml_f="9557" txt_i="3076" txt_f="3082">, 2004</offsets></xref><offsets xml_i="9564" xml_f="9566" txt_i="3082" txt_f="3084">).</offsets></p><p><offsets xml_i="9573" xml_f="9767" txt_i="3085" txt_f="3279">Many phase I/II trials reported promising response rates and safety results for adding bevacizumab prior and concurrent to 5-fluorouracil (5-FU)-based CRT in the preoperative treatment of LARC (</offsets><xref ref-type="bibr" rid="bib62"><offsets xml_i="9801" xml_f="9812" txt_i="3279" txt_f="3290">Verstraete </offsets><italic><offsets xml_i="9820" xml_f="9825" txt_i="3290" txt_f="3295">et al</offsets></italic><offsets xml_i="9834" xml_f="9840" txt_i="3295" txt_f="3301">, 2012</offsets></xref><offsets xml_i="9847" xml_f="10087" txt_i="3301" txt_f="3541">). However, the pathological complete response (pCR) rate between similar studies varied between 13 and 40%, stressing the importance of a good selection of patients for this combination treatment. Some trials reported pCR rates below 20% (</offsets><xref ref-type="bibr" rid="bib11"><offsets xml_i="10121" xml_f="10127" txt_i="3541" txt_f="3547">Czito </offsets><italic><offsets xml_i="10135" xml_f="10140" txt_i="3547" txt_f="3552">et al</offsets></italic><offsets xml_i="10149" xml_f="10155" txt_i="3552" txt_f="3558">, 2007</offsets></xref><offsets xml_i="10162" xml_f="10164" txt_i="3558" txt_f="3560">; </offsets><xref ref-type="bibr" rid="bib69"><offsets xml_i="10198" xml_f="10206" txt_i="3560" txt_f="3568">Willett </offsets><italic><offsets xml_i="10214" xml_f="10219" txt_i="3568" txt_f="3573">et al</offsets></italic><offsets xml_i="10228" xml_f="10234" txt_i="3573" txt_f="3579">, 2010</offsets></xref><offsets xml_i="10241" xml_f="10243" txt_i="3579" txt_f="3581">; </offsets><xref ref-type="bibr" rid="bib36"><offsets xml_i="10277" xml_f="10286" txt_i="3581" txt_f="3590">Kennecke </offsets><italic><offsets xml_i="10294" xml_f="10299" txt_i="3590" txt_f="3595">et al</offsets></italic><offsets xml_i="10308" xml_f="10314" txt_i="3595" txt_f="3601">, 2012</offsets></xref><offsets xml_i="10321" xml_f="10323" txt_i="3601" txt_f="3603">; </offsets><xref ref-type="bibr" rid="bib13"><offsets xml_i="10357" xml_f="10364" txt_i="3603" txt_f="3610">Dellas </offsets><italic><offsets xml_i="10372" xml_f="10377" txt_i="3610" txt_f="3615">et al</offsets></italic><offsets xml_i="10386" xml_f="10392" txt_i="3615" txt_f="3621">, 2013</offsets></xref><offsets xml_i="10399" xml_f="10401" txt_i="3621" txt_f="3623">; </offsets><xref ref-type="bibr" rid="bib42"><offsets xml_i="10435" xml_f="10442" txt_i="3623" txt_f="3630">Landry </offsets><italic><offsets xml_i="10450" xml_f="10455" txt_i="3630" txt_f="3635">et al</offsets></italic><offsets xml_i="10464" xml_f="10470" txt_i="3635" txt_f="3641">, 2013</offsets></xref><offsets xml_i="10477" xml_f="10596" txt_i="3641" txt_f="3760">), which is not better than trials reported with 5-FU-based CRT alone. However, others reported higher response rates (</offsets><xref ref-type="bibr" rid="bib68"><offsets xml_i="10630" xml_f="10638" txt_i="3760" txt_f="3768">Willett </offsets><italic><offsets xml_i="10646" xml_f="10651" txt_i="3768" txt_f="3773">et al</offsets></italic><offsets xml_i="10660" xml_f="10666" txt_i="3773" txt_f="3779">, 2005</offsets></xref><offsets xml_i="10673" xml_f="10675" txt_i="3779" txt_f="3781">; </offsets><xref ref-type="bibr" rid="bib10"><offsets xml_i="10709" xml_f="10715" txt_i="3781" txt_f="3787">Crane </offsets><italic><offsets xml_i="10723" xml_f="10728" txt_i="3787" txt_f="3792">et al</offsets></italic><offsets xml_i="10737" xml_f="10743" txt_i="3792" txt_f="3798">, 2010</offsets></xref><offsets xml_i="10750" xml_f="10752" txt_i="3798" txt_f="3800">; </offsets><xref ref-type="bibr" rid="bib40"><offsets xml_i="10786" xml_f="10798" txt_i="3800" txt_f="3812">Koukourakis </offsets><italic><offsets xml_i="10806" xml_f="10811" txt_i="3812" txt_f="3817">et al</offsets></italic><offsets xml_i="10820" xml_f="10826" txt_i="3817" txt_f="3823">, 2011</offsets></xref><offsets xml_i="10833" xml_f="10835" txt_i="3823" txt_f="3825">; </offsets><xref ref-type="bibr" rid="bib48"><offsets xml_i="10869" xml_f="10875" txt_i="3825" txt_f="3831">Nogue </offsets><italic><offsets xml_i="10883" xml_f="10888" txt_i="3831" txt_f="3836">et al</offsets></italic><offsets xml_i="10897" xml_f="10903" txt_i="3836" txt_f="3842">, 2011</offsets></xref><offsets xml_i="10910" xml_f="10912" txt_i="3842" txt_f="3844">; </offsets><xref ref-type="bibr" rid="bib49"><offsets xml_i="10946" xml_f="10952" txt_i="3844" txt_f="3850">Resch </offsets><italic><offsets xml_i="10960" xml_f="10965" txt_i="3850" txt_f="3855">et al</offsets></italic><offsets xml_i="10974" xml_f="10980" txt_i="3855" txt_f="3861">, 2012</offsets></xref><offsets xml_i="10987" xml_f="10989" txt_i="3861" txt_f="3863">; </offsets><xref ref-type="bibr" rid="bib59"><offsets xml_i="11023" xml_f="11030" txt_i="3863" txt_f="3870">Spigel </offsets><italic><offsets xml_i="11038" xml_f="11043" txt_i="3870" txt_f="3875">et al</offsets></italic><offsets xml_i="11052" xml_f="11058" txt_i="3875" txt_f="3881">, 2012</offsets></xref><offsets xml_i="11065" xml_f="11308" txt_i="3881" txt_f="4124">), indicating that the addition of bevacizumab possibly offers higher efficacy to a subgroup of patients. Unfortunately, there are no prospectively validated biomarkers of response, toxicity or resistance to anti-angiogenic therapy available (</offsets><xref ref-type="bibr" rid="bib41"><offsets xml_i="11342" xml_f="11353" txt_i="4124" txt_f="4135">Lambrechts </offsets><italic><offsets xml_i="11361" xml_f="11366" txt_i="4135" txt_f="4140">et al</offsets></italic><offsets xml_i="11375" xml_f="11381" txt_i="4140" txt_f="4146">, 2013</offsets></xref><offsets xml_i="11388" xml_f="11504" txt_i="4146" txt_f="4262">). Moreover, the exact effect of bevacizumab on rectal tumours has not been fully elucidated yet. Only the group of </offsets><xref ref-type="bibr" rid="bib67"><offsets xml_i="11538" xml_f="11546" txt_i="4262" txt_f="4270">Willett </offsets><italic><offsets xml_i="11554" xml_f="11559" txt_i="4270" txt_f="4275">et al</offsets></italic><offsets xml_i="11568" xml_f="11574" txt_i="4275" txt_f="4281"> (2004</offsets></xref><offsets xml_i="11581" xml_f="11583" txt_i="4281" txt_f="4283">, </offsets><xref ref-type="bibr" rid="bib68"><offsets xml_i="11617" xml_f="11621" txt_i="4283" txt_f="4287">2005</offsets></xref><offsets xml_i="11628" xml_f="11630" txt_i="4287" txt_f="4289">, </offsets><xref ref-type="bibr" rid="bib70"><offsets xml_i="11664" xml_f="11668" txt_i="4289" txt_f="4293">2009</offsets></xref><offsets xml_i="11675" xml_f="11736" txt_i="4293" txt_f="4354">) analysed extensively the impact of bevacizumab monotherapy.</offsets></p><p><offsets xml_i="11743" xml_f="12014" txt_i="4355" txt_f="4626">Accordingly, better insights in the effect of bevacizumab alone and in the molecular interaction between anti-angiogenic agents and CRT are necessary to optimise this combination treatment for LARC and to allow understanding why some subgroups respond better than others.</offsets></p><p><offsets xml_i="12021" xml_f="12392" txt_i="4627" txt_f="4998">In our study, rectal cancer patients were treated with a combination of bevacizumab, chemotherapy (capecitabin +/− oxaliplatin) and radiotherapy (AXEBeam study). The addition of oxaliplatin to fluoropyrimidine-based CRT was investigated before in several phase III trials. Apart from one report, in which the treatment schedule in the control groups might be suboptimal (</offsets><xref ref-type="bibr" rid="bib50"><offsets xml_i="12426" xml_f="12432" txt_i="4998" txt_f="5004">Rodel </offsets><italic><offsets xml_i="12440" xml_f="12445" txt_i="5004" txt_f="5009">et al</offsets></italic><offsets xml_i="12454" xml_f="12460" txt_i="5009" txt_f="5015">, 2012</offsets></xref><offsets xml_i="12467" xml_f="12538" txt_i="5015" txt_f="5086">), no improvement in pCR rate was detected when oxaliplatin was added (</offsets><xref ref-type="bibr" rid="bib24"><offsets xml_i="12572" xml_f="12579" txt_i="5086" txt_f="5093">Gerard </offsets><italic><offsets xml_i="12587" xml_f="12592" txt_i="5093" txt_f="5098">et al</offsets></italic><offsets xml_i="12601" xml_f="12607" txt_i="5098" txt_f="5104">, 2010</offsets></xref><offsets xml_i="12614" xml_f="12616" txt_i="5104" txt_f="5106">; </offsets><xref ref-type="bibr" rid="bib4"><offsets xml_i="12649" xml_f="12657" txt_i="5106" txt_f="5114">Aschele </offsets><italic><offsets xml_i="12665" xml_f="12670" txt_i="5114" txt_f="5119">et al</offsets></italic><offsets xml_i="12679" xml_f="12685" txt_i="5119" txt_f="5125">, 2011</offsets></xref><offsets xml_i="12692" xml_f="12694" txt_i="5125" txt_f="5127">; </offsets><xref ref-type="bibr" rid="bib51"><offsets xml_i="12728" xml_f="12732" txt_i="5127" txt_f="5131">Roh </offsets><italic><offsets xml_i="12740" xml_f="12745" txt_i="5131" txt_f="5136">et al</offsets></italic><offsets xml_i="12754" xml_f="12760" txt_i="5136" txt_f="5142">, 2011</offsets></xref><offsets xml_i="12767" xml_f="12937" txt_i="5142" txt_f="5312">). Therefore, we included in most of our analysis both patients that were treated with and without oxaliplatin, assuming that they would have similar treatment responses.</offsets></p><p><offsets xml_i="12944" xml_f="13475" txt_i="5313" txt_f="5844">The main aim was to get more insight into the molecular effects of bevacizumab by studying bevacizumab-induced changes on gene expression level and different markers in blood and tissue samples in 59 included patients. In addition, we performed a subordinate exploratory analysis to identify possible key factors in the combined treatment of bevacizumab with CRT, and assessed their prognostic potential. However, the setup of this study only allows us to address relationships descriptively; no causal associations can be defined.</offsets></p><sec sec-type="materials|methods"><title><offsets xml_i="13520" xml_f="13541" txt_i="5845" txt_f="5866">Materials and Methods</offsets></title><sec><title><offsets xml_i="13561" xml_f="13601" txt_i="5867" txt_f="5907">Patient selection, treatment and outcome</offsets></title><p><offsets xml_i="13612" xml_f="13877" txt_i="5908" txt_f="6173">In a Belgian investigator-driven multicentric randomised phase II study (AXEBeam, NCT00828672), 84 patients with advanced rectal cancer with bad prognostic factors (T2-3Nx with tight or threatened resection margins, T4Nx) have been treated with bevacizumab (5 mg kg</offsets><sup><offsets xml_i="13882" xml_f="13884" txt_i="6173" txt_f="6175">−1</offsets></sup><offsets xml_i="13890" xml_f="13935" txt_i="6175" txt_f="6220">) in combination with capecitabine (1650 mg m</offsets><sup><offsets xml_i="13940" xml_f="13942" txt_i="6220" txt_f="6222">−2</offsets></sup><offsets xml_i="13948" xml_f="14024" txt_i="6222" txt_f="6298"> per day) and radiotherapy (45 Gy, 1.8 Gy per day) with oxaliplatin (50 mg m</offsets><sup><offsets xml_i="14029" xml_f="14031" txt_i="6298" txt_f="6300">−2</offsets></sup><offsets xml_i="14037" xml_f="14077" txt_i="6300" txt_f="6340">; arm A) or without oxaliplatin (arm B; </offsets><xref ref-type="supplementary-material" rid="sup1"><offsets xml_i="14128" xml_f="14151" txt_i="6340" txt_f="6363">Supplementary Figure e1</offsets></xref><offsets xml_i="14158" xml_f="14307" txt_i="6363" txt_f="6512">). The study was approved by a central Independent Ethics Committee and 59 patients gave informed consent to use samples for translational research. </offsets><xref rid="tbl1" ref-type="table"><offsets xml_i="14341" xml_f="14348" txt_i="6512" txt_f="6519">Table 1</offsets></xref><offsets xml_i="14355" xml_f="14631" txt_i="6519" txt_f="6795"> lists the patient characteristics and clinical outcomes of those 59 patients. For data analysis, the pathological response was used to differentiate responders (pCR) from non-responders (no pCR). In addition, tumour regression was graded by using the Dworak regression grade.</offsets></p></sec><sec><title><offsets xml_i="14653" xml_f="14683" txt_i="6797" txt_f="6827">Sample collections and storage</offsets></title><p><offsets xml_i="14694" xml_f="14968" txt_i="6828" txt_f="7102">Tumour tissue and blood samples were collected before treatment (T0) and after the first loading dose of bevacizumab but before CRT (T1). Extra blood samples were taken after two (T2) doses of bevacizumab (during CRT). Biopsies of healthy mucosa (M) were taken at baseline (</offsets><xref ref-type="supplementary-material" rid="sup1"><offsets xml_i="15019" xml_f="15042" txt_i="7102" txt_f="7125">Supplementary Figure e1</offsets></xref><offsets xml_i="15049" xml_f="15051" txt_i="7125" txt_f="7127">).</offsets></p><p><offsets xml_i="15058" xml_f="15303" txt_i="7128" txt_f="7373">Biopsies for RNA extraction were fixed in RNA later (Qiagen GmbH, Hilden, Germany) and stored at −80 °C. Biopsies for tissue analysis were fixed in 4% formalin for paraffin embedding. The number of samples used for each analysis is indicated in </offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="15335" xml_f="15343" txt_i="7373" txt_f="7381">Figure 1</offsets></xref><offsets xml_i="15350" xml_f="15379" txt_i="7381" txt_f="7410"> with a detailed overview in </offsets><xref ref-type="supplementary-material" rid="sup1"><offsets xml_i="15430" xml_f="15452" txt_i="7410" txt_f="7432">Supplementary Table e1</offsets></xref><offsets xml_i="15459" xml_f="15460" txt_i="7432" txt_f="7433">.</offsets></p></sec><sec><title><offsets xml_i="15482" xml_f="15494" txt_i="7435" txt_f="7447">ELISA assays</offsets></title><p><offsets xml_i="15505" xml_f="15717" txt_i="7448" txt_f="7660">Enzyme-linked immunosorbent assays (ELISA) to measure circulating levels of PDGF-AA, PDGF-BB, thrombospondin-1, IL-8, angiopoietin-2 and CYR61 were performed on blood samples of all 59 patients at T0, T1 and T2 (</offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="15749" xml_f="15757" txt_i="7660" txt_f="7668">Figure 1</offsets></xref><offsets xml_i="15764" xml_f="16229" txt_i="7668" txt_f="8125">). Quantikine R&amp;D System kits (R&amp;D Systems, Inc., Minneapolis, MN, USA) were used and the individual manufacturer's instructions of the kits were followed. The optical density was determined using the microplate reader Multiscan FC (Thermo Scientific, Waltham, MA, USA) set to 450 nm, with a wavelength correction set to 540 nm. Patient samples were tested in duplicate and the mean value was used for analysis. Results of all levels were expressed as pg ml</offsets><sup><offsets xml_i="16234" xml_f="16236" txt_i="8125" txt_f="8127">−1</offsets></sup><offsets xml_i="16242" xml_f="16251" txt_i="8127" txt_f="8136"> or ng ml</offsets><sup><offsets xml_i="16256" xml_f="16258" txt_i="8136" txt_f="8138">−1</offsets></sup><offsets xml_i="16264" xml_f="16394" txt_i="8138" txt_f="8268"> and calculated as median values±s.d. Extra ELISA and luminex analysis performed on a subset of the patient group can be found in </offsets><xref ref-type="supplementary-material" rid="sup1"><offsets xml_i="16445" xml_f="16480" txt_i="8268" txt_f="8303">Supplementary Materials and Methods</offsets></xref><offsets xml_i="16487" xml_f="16488" txt_i="8303" txt_f="8304">.</offsets></p></sec><sec><title><offsets xml_i="16510" xml_f="16542" txt_i="8306" txt_f="8338">Immunohistochemistry and scoring</offsets></title><p><offsets xml_i="16553" xml_f="16787" txt_i="8339" txt_f="8573">The paraffin-embedded tissues of 59 patients taken at T0 and T1 were stained for haematoxylin–eosin to identify tumour. They were analysed by an experienced pathologist, and biopsies without tumour were excluded from the analysis (T0 </offsets><italic><offsets xml_i="16795" xml_f="16796" txt_i="8573" txt_f="8574">n</offsets></italic><offsets xml_i="16805" xml_f="16812" txt_i="8574" txt_f="8581">=9; T1 </offsets><italic><offsets xml_i="16820" xml_f="16821" txt_i="8581" txt_f="8582">n</offsets></italic><offsets xml_i="16830" xml_f="16956" txt_i="8582" txt_f="8708">=12). Immunohistochemical (IHC) analysis was performed on biopsies from 50 and 47 patients taken, respectively, at T0 and T1 (</offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="16988" xml_f="16996" txt_i="8708" txt_f="8716">Figure 1</offsets></xref><offsets xml_i="17003" xml_f="17005" txt_i="8716" txt_f="8718">).</offsets></p><p><offsets xml_i="17012" xml_f="17060" txt_i="8719" txt_f="8767">Sections were stained for CD31/34 combined with </offsets><italic><offsets xml_i="17068" xml_f="17069" txt_i="8767" txt_f="8768">α</offsets></italic><offsets xml_i="17078" xml_f="17460" txt_i="8768" txt_f="9150">-SMA as a measure for blood vessel maturation. CA-IX was used as marker of hypoxia. Endogenous peroxidase activity was blocked followed by antigen retrieval and a blocking step. Samples were incubated with primary antibodies and stainings were visualised using secondary antibodies followed by DAB or Vector Vip incubation. Detailed specifications on the IHC staining are listed in </offsets><xref ref-type="supplementary-material" rid="sup1"><offsets xml_i="17511" xml_f="17533" txt_i="9150" txt_f="9172">Supplementary Table e2</offsets></xref><offsets xml_i="17540" xml_f="17541" txt_i="9172" txt_f="9173">.</offsets></p><p><offsets xml_i="17548" xml_f="17700" txt_i="9174" txt_f="9326">Quantitative analysis of the immunostained histological sections for microvessel density (MVD) and CA-IX expression was performed as described earlier (</offsets><xref ref-type="bibr" rid="bib61"><offsets xml_i="17734" xml_f="17745" txt_i="9326" txt_f="9337">Verstraete </offsets><italic><offsets xml_i="17753" xml_f="17758" txt_i="9337" txt_f="9342">et al</offsets></italic><offsets xml_i="17767" xml_f="17773" txt_i="9342" txt_f="9348">, 2013</offsets></xref><offsets xml_i="17780" xml_f="17827" txt_i="9348" txt_f="9395">). CD31/34-stained blood vessels surrounded by </offsets><italic><offsets xml_i="17835" xml_f="17836" txt_i="9395" txt_f="9396">α</offsets></italic><offsets xml_i="17845" xml_f="18111" txt_i="9396" txt_f="9662">-SMA positivity were counted in 10 high density fields to calculate the percentage of pericyte-covered blood vessels. Several slides were reviewed by an independent observer, and no disagreement in score was found. Median values are described in the Results section.</offsets></p><p><offsets xml_i="18118" xml_f="18183" txt_i="9663" txt_f="9728">Details about the Ki67 and cleaved PARP staining can be found in </offsets><xref ref-type="supplementary-material" rid="sup1"><offsets xml_i="18234" xml_f="18256" txt_i="9728" txt_f="9750">Supplementary Table e5</offsets></xref><offsets xml_i="18263" xml_f="18268" txt_i="9750" txt_f="9755"> and </offsets><xref ref-type="supplementary-material" rid="sup1"><offsets xml_i="18319" xml_f="18354" txt_i="9755" txt_f="9790">Supplementary Materials and Methods</offsets></xref><offsets xml_i="18361" xml_f="18362" txt_i="9790" txt_f="9791">.</offsets></p></sec><sec><title><offsets xml_i="18384" xml_f="18417" txt_i="9793" txt_f="9826">RNA extraction and cDNA synthesis</offsets></title><p><offsets xml_i="18428" xml_f="18587" txt_i="9827" txt_f="9986">Gene expression levels were analysed on tissue of patients from treatment arm A only in order to assess a homogenous cohort. Tissue included mucosal biopsies (</offsets><italic><offsets xml_i="18595" xml_f="18596" txt_i="9986" txt_f="9987">n</offsets></italic><offsets xml_i="18605" xml_f="18634" txt_i="9987" txt_f="10016">=18) and tumour taken at T0 (</offsets><italic><offsets xml_i="18642" xml_f="18643" txt_i="10016" txt_f="10017">n</offsets></italic><offsets xml_i="18652" xml_f="18673" txt_i="10017" txt_f="10038">=16), as well as T1 (</offsets><italic><offsets xml_i="18681" xml_f="18682" txt_i="10038" txt_f="10039">n</offsets></italic><offsets xml_i="18691" xml_f="18696" txt_i="10039" txt_f="10044">=13; </offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="18728" xml_f="18736" txt_i="10044" txt_f="10052">Figure 1</offsets></xref><offsets xml_i="18743" xml_f="18745" txt_i="10052" txt_f="10054">).</offsets></p><p><offsets xml_i="18752" xml_f="19413" txt_i="10055" txt_f="10713">Tissue was broken down by combination of physical (Dounce homogeniser) and chemical homogenisation (Trizol, Invitrogen, Life Technologies Europe B.V.) and RNA was isolated by means of RNeasy Kit (Qiagen, Chatsworth, CA, USA) according to the manufacturer's instructions. RNA quality and quantity was determined by NanoDrop spectrophotometer (NanoDrop Technologies, Centreville, DE, USA) and by means of the Agilent 2100 BioAnalyzer (Agilent, Palo Alto, CA, USA). Only RNA showing no signs of degradation or impurities (260/280 and 260/230 nm ratios, &gt;1.8) was considered suitable for microarray analysis and used for labelling. cDNA was synthesised from 2.5 </offsets><italic><offsets xml_i="19421" xml_f="19422" txt_i="10713" txt_f="10714">μ</offsets></italic><offsets xml_i="19431" xml_f="19569" txt_i="10714" txt_f="10852">g of RNA using SuperScript II reverse transcriptase and random hexamer primers (Invitrogen, Life Technologies Europe B.V., Gent, Belgium).</offsets></p></sec><sec><title><offsets xml_i="19591" xml_f="19621" txt_i="10854" txt_f="10884">Microarray and data processing</offsets></title><p><offsets xml_i="19632" xml_f="19953" txt_i="10885" txt_f="11206">Microarray hybridisation procedure was performed on Affymetrix Primeview arrays according to the manufacturer's instructions (Affymetrix Inc., Santa Clara, CA, USA). Analysis of the microarray data was performed in the R programming environment in conjunction with the packages developed within the Bioconductor project (</offsets><xref ref-type="bibr" rid="bib23"><offsets xml_i="19987" xml_f="19997" txt_i="11206" txt_f="11216">Gentleman </offsets><italic><offsets xml_i="20005" xml_f="20010" txt_i="11216" txt_f="11221">et al</offsets></italic><offsets xml_i="20019" xml_f="20025" txt_i="11221" txt_f="11227">, 2004</offsets></xref><offsets xml_i="20032" xml_f="20090" txt_i="11227" txt_f="11285">). Differential expression was assessed via the moderated </offsets><italic><offsets xml_i="20098" xml_f="20099" txt_i="11285" txt_f="11286">t</offsets></italic><offsets xml_i="20108" xml_f="20132" txt_i="11286" txt_f="11310">-statistic described by </offsets><xref ref-type="bibr" rid="bib57"><offsets xml_i="20166" xml_f="20178" txt_i="11310" txt_f="11322">Smyth (2004)</offsets></xref><offsets xml_i="20185" xml_f="20240" txt_i="11322" txt_f="11377"> and implemented in the limma package (version 3.12.1; </offsets><xref ref-type="bibr" rid="bib23"><offsets xml_i="20274" xml_f="20284" txt_i="11377" txt_f="11387">Gentleman </offsets><italic><offsets xml_i="20292" xml_f="20297" txt_i="11387" txt_f="11392">et al</offsets></italic><offsets xml_i="20306" xml_f="20312" txt_i="11392" txt_f="11398">, 2004</offsets></xref><offsets xml_i="20319" xml_f="20418" txt_i="11398" txt_f="11497">). To control the false-discovery rate, multiple testing correction was performed by the method of </offsets><xref ref-type="bibr" rid="bib6"><offsets xml_i="20451" xml_f="20480" txt_i="11497" txt_f="11526">Benjamini and Hochberg (1995)</offsets></xref><offsets xml_i="20487" xml_f="20784" txt_i="11526" txt_f="11823">. Data are publically available through National Center for Biotechnology Information (GSE60331). Cluster analysis distinguished the tumour biopsies (T0 and T1) from the normal mucosal biopsies (M). Tumour biopsies that clustered together with the mucosal biopsies were excluded from the analysis.</offsets></p></sec><sec><title><offsets xml_i="20806" xml_f="20822" txt_i="11825" txt_f="11841">Pathway analysis</offsets></title><p><offsets xml_i="20833" xml_f="20954" txt_i="11842" txt_f="11963">Gene enrichment and pathway analysis was performed with the web-based DAVID Bioinformatics Resource 6.7 programme suite (</offsets><ext-link ext-link-type="uri" xlink:href="http://david.abcc.ncifcrf.gov/"><offsets xml_i="21028" xml_f="21058" txt_i="11963" txt_f="11993">http://david.abcc.ncifcrf.gov/</offsets></ext-link><offsets xml_i="21069" xml_f="21072" txt_i="11993" txt_f="11996">) (</offsets><xref ref-type="bibr" rid="bib30"><offsets xml_i="21106" xml_f="21112" txt_i="11996" txt_f="12002">Huang </offsets><italic><offsets xml_i="21120" xml_f="21125" txt_i="12002" txt_f="12007">et al</offsets></italic><offsets xml_i="21134" xml_f="21140" txt_i="12007" txt_f="12013">, 2009</offsets></xref><offsets xml_i="21147" xml_f="21273" txt_i="12013" txt_f="12139">). Analysis was performed on the list of upregulated and downregulated genes with a fold change of ⩾1 or ⩽−1 (and a corrected </offsets><italic><offsets xml_i="21281" xml_f="21282" txt_i="12139" txt_f="12140">P</offsets></italic><offsets xml_i="21291" xml_f="21574" txt_i="12140" txt_f="12420">&lt;0.001 for the comparison between tumour and mucosa samples). The Kyoto Encyclopedia of Genes and Genomes pathways and the Gene Ontology (GO) terms of biological processes in DAVID were used to categorise enriched biological themes (significance level after Bonferonni correction </offsets><italic><offsets xml_i="21582" xml_f="21583" txt_i="12420" txt_f="12421">P</offsets></italic><offsets xml_i="21592" xml_f="21717" txt_i="12421" txt_f="12543">&lt;0.05). To explore functional interactions or partnership between the genes we loaded them into the STRING 9.1 programme (</offsets><ext-link ext-link-type="uri" xlink:href="http://string-db.org/"><offsets xml_i="21782" xml_f="21803" txt_i="12543" txt_f="12564">http://string-db.org/</offsets></ext-link><offsets xml_i="21814" xml_f="21816" txt_i="12564" txt_f="12566">; </offsets><xref ref-type="bibr" rid="bib17"><offsets xml_i="21850" xml_f="21863" txt_i="12566" txt_f="12579">Franceschini </offsets><italic><offsets xml_i="21871" xml_f="21876" txt_i="12579" txt_f="12584">et al</offsets></italic><offsets xml_i="21885" xml_f="21891" txt_i="12584" txt_f="12590">, 2013</offsets></xref><offsets xml_i="21898" xml_f="21900" txt_i="12590" txt_f="12592">).</offsets></p></sec><sec><title><offsets xml_i="21922" xml_f="21942" txt_i="12594" txt_f="12614">Statistical analysis</offsets></title><p><offsets xml_i="21953" xml_f="22341" txt_i="12615" txt_f="13003">The Mann–Whitney test or Kruskal–Wallis test was applied when appropriate to compare the expression of the blood and tissue markers at the different time points to evaluate the on-treatment changes. The comparison of the circulating and tissue expression levels between the responders and non-responders, as classified according to the pathological response, was done by the Mann–Whitney </offsets><italic><offsets xml_i="22349" xml_f="22350" txt_i="13003" txt_f="13004">U</offsets></italic><offsets xml_i="22359" xml_f="22434" txt_i="13004" txt_f="13079">-test and for the Dworak regression grade using the Kruskal–Wallis test. A </offsets><italic><offsets xml_i="22442" xml_f="22443" txt_i="13079" txt_f="13080">t</offsets></italic><offsets xml_i="22452" xml_f="22661" txt_i="13080" txt_f="13289">-test was used to compare treatment-induced changes (T1/T0 and T2/T0) of gene and protein expression levels between patients with and without a pCR. Median reported in Results section. A significance level of </offsets><italic><offsets xml_i="22669" xml_f="22670" txt_i="13289" txt_f="13290">P</offsets></italic><offsets xml_i="22679" xml_f="22830" txt_i="13290" txt_f="13441">=0.05 was used in all cases. Statistical analysis was done using Statistica software 12 (StatSoft Inc., Tulsa, OK, USA) and the R statistical language.</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="22877" xml_f="22884" txt_i="13444" txt_f="13451">Results</offsets></title><sec><title><offsets xml_i="22904" xml_f="22978" txt_i="13452" txt_f="13526">Impact of bevacizumab on gene expression, blood markers and tissue markers</offsets></title><p><offsets xml_i="22989" xml_f="23409" txt_i="13527" txt_f="13947">To evaluate biomarker responses to bevacizumab treatment and to unravel its mechanism of action, we profiled gene expression changes by characterising the molecular consequences in response to one or two doses of bevacizumab. To achieve this, tumour biopsies obtained at baseline (T0) and after a single dose of bevacizumab (T1) were compared using microarray analysis and validated with ELISA and IHC at T0, T1 and T2 (</offsets><xref ref-type="supplementary-material" rid="sup1"><offsets xml_i="23460" xml_f="23483" txt_i="13947" txt_f="13970">Supplementary Figure e1</offsets></xref><offsets xml_i="23490" xml_f="23495" txt_i="13970" txt_f="13975"> and </offsets><xref ref-type="supplementary-material" rid="sup1"><offsets xml_i="23546" xml_f="23568" txt_i="13975" txt_f="13997">Supplementary Table e1</offsets></xref><offsets xml_i="23575" xml_f="23577" txt_i="13997" txt_f="13999">).</offsets></p></sec><sec><title><offsets xml_i="23599" xml_f="23652" txt_i="14001" txt_f="14054">Changes in gene expression in response to bevacizumab</offsets></title><p><offsets xml_i="23663" xml_f="23811" txt_i="14055" txt_f="14197">The microarray data revealed that one dose of bevacizumab changed the expression of only 14 genes in all patients (fold change of &gt;1 or &lt;−1; (</offsets><xref ref-type="supplementary-material" rid="sup1"><offsets xml_i="23862" xml_f="23884" txt_i="14197" txt_f="14219">Supplementary Table e3</offsets></xref><offsets xml_i="23891" xml_f="24204" txt_i="14219" txt_f="14532">). Considering separate outcomes, 71 and 31 genes showed altered expression in patients with a pCR and without a pCR respectively. A functional annotation analysis of the gene changes in the responders showed significant enrichment of angiogenesis-related GO biological processes derived from nine altered genes (</offsets><xref rid="tbl2" ref-type="table"><offsets xml_i="24238" xml_f="24245" txt_i="14532" txt_f="14539">Table 2</offsets></xref><offsets xml_i="24252" xml_f="24338" txt_i="14539" txt_f="14625">). No significant enriched biological processes could be found for the non-responders.</offsets></p><p><offsets xml_i="24345" xml_f="24369" txt_i="14626" txt_f="14650">Among those nine genes (</offsets><italic><offsets xml_i="24377" xml_f="24414" txt_i="14650" txt_f="14687">FLT1, IL-8, PDGFA, CTGF, ROBO4, ENPEP</offsets></italic><offsets xml_i="24423" xml_f="24425" txt_i="14687" txt_f="14689">, </offsets><italic><offsets xml_i="24433" xml_f="24446" txt_i="14689" txt_f="14702">THBS1, ANGPT2</offsets></italic><offsets xml_i="24455" xml_f="24460" txt_i="14702" txt_f="14707"> and </offsets><italic><offsets xml_i="24468" xml_f="24474" txt_i="14707" txt_f="14713">CYR61)</offsets></italic><offsets xml_i="24483" xml_f="24494" txt_i="14713" txt_f="14724">, only for </offsets><italic><offsets xml_i="24502" xml_f="24507" txt_i="14724" txt_f="14729">PDGFA</offsets></italic><offsets xml_i="24516" xml_f="24636" txt_i="14729" txt_f="14849">, a relevant difference was found in bevacizumab-induced changes in expression between patients with and without a pCR (</offsets><italic><offsets xml_i="24644" xml_f="24645" txt_i="14849" txt_f="14850">P</offsets></italic><offsets xml_i="24654" xml_f="24673" txt_i="14850" txt_f="14869">=0.1). As shown in </offsets><xref ref-type="supplementary-material" rid="sup1"><offsets xml_i="24724" xml_f="24747" txt_i="14869" txt_f="14892">Supplementary Figure e2</offsets></xref><offsets xml_i="24754" xml_f="24756" txt_i="14892" txt_f="14894">, </offsets><italic><offsets xml_i="24764" xml_f="24769" txt_i="14894" txt_f="14899">PDGFA</offsets></italic><offsets xml_i="24778" xml_f="24978" txt_i="14899" txt_f="15099"> expression decreased in responders with almost 10% after bevacizumab treatment (T1/T0=(0.8–0.9)), whereas almost no bevacizumab-induced decrease was observed in the non-responders (T1/T0=(0.88–1.1)).</offsets></p></sec><sec><title><offsets xml_i="25000" xml_f="25063" txt_i="15101" txt_f="15164">Changes in circulating marker levels in response to bevacizumab</offsets></title><p><offsets xml_i="25074" xml_f="25569" txt_i="15165" txt_f="15660">Six circulating markers (PDGF-AA, PDGF-BB, thrombospondin-1, IL-8, angiopoietin-2 and CYR61), selected based on the microarray results and literature, were quantified by ELISA. None of these markers showed significant changes in circulating levels between T0 and T1. However, small but significant treatment-induced changes between T0 and T2 were observed for PDGF-AA, PDGF-BB, thrombospondin-1, angiopietin-2 and IL-8. The median level and range for each biomarker at T0, T1 and T2 is shown in </offsets><xref ref-type="supplementary-material" rid="sup1"><offsets xml_i="25620" xml_f="25642" txt_i="15660" txt_f="15682">Supplementary Table e4</offsets></xref><offsets xml_i="25649" xml_f="25650" txt_i="15682" txt_f="15683">.</offsets></p><p><offsets xml_i="25657" xml_f="25970" txt_i="15684" txt_f="15997">When comparing treatment-induced changes in patients with and without a pCR, most proteins showed similar declines in both patient groups (data not shown). Only for PDGF-AA and PDGF-BB, modest differences could be observed between T0 and T2. Responding patients showed a larger decrease (from 575.9 to 331.5 pg ml</offsets><sup><offsets xml_i="25975" xml_f="25977" txt_i="15997" txt_f="15999">−1</offsets></sup><offsets xml_i="25983" xml_f="25985" txt_i="15999" txt_f="16001">; </offsets><italic><offsets xml_i="25993" xml_f="25994" txt_i="16001" txt_f="16002">P</offsets></italic><offsets xml_i="26003" xml_f="26105" txt_i="16002" txt_f="16104">=0.11) in PDGF-AA levels between T0 and T2 compared with the non-responders (from 704.1 to 539.7 pg ml</offsets><sup><offsets xml_i="26110" xml_f="26112" txt_i="16104" txt_f="16106">−1</offsets></sup><offsets xml_i="26118" xml_f="26120" txt_i="16106" txt_f="16108">; </offsets><italic><offsets xml_i="26128" xml_f="26129" txt_i="16108" txt_f="16109">P</offsets></italic><offsets xml_i="26138" xml_f="26145" txt_i="16109" txt_f="16116">=0.06, </offsets><italic><offsets xml_i="26153" xml_f="26154" txt_i="16116" txt_f="16117">P</offsets></italic><offsets xml_i="26163" xml_f="26170" txt_i="16117" txt_f="16124">=0.06; </offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="26202" xml_f="26218" txt_i="16124" txt_f="16140">Figures 2A and B</offsets></xref><offsets xml_i="26225" xml_f="26350" txt_i="16140" txt_f="16265">). For PDGF-BB, the treatment-induced changes were significantly larger in responding compared with non-responding patients (</offsets><italic><offsets xml_i="26358" xml_f="26359" txt_i="16265" txt_f="16266">P</offsets></italic><offsets xml_i="26368" xml_f="26444" txt_i="16266" txt_f="16342">=0.002) with a significant decrease in responders (from 430.5 to 206.2 pg ml</offsets><sup><offsets xml_i="26449" xml_f="26451" txt_i="16342" txt_f="16344">−1</offsets></sup><offsets xml_i="26457" xml_f="26459" txt_i="16344" txt_f="16346">; </offsets><italic><offsets xml_i="26467" xml_f="26468" txt_i="16346" txt_f="16347">P</offsets></italic><offsets xml_i="26477" xml_f="26553" txt_i="16347" txt_f="16423">=0.03) and almost no alteration in non-responders (from 452.5 to 343.1 pg ml</offsets><sup><offsets xml_i="26558" xml_f="26560" txt_i="16423" txt_f="16425">−1</offsets></sup><offsets xml_i="26566" xml_f="26568" txt_i="16425" txt_f="16427">; </offsets><italic><offsets xml_i="26576" xml_f="26577" txt_i="16427" txt_f="16428">P</offsets></italic><offsets xml_i="26586" xml_f="26593" txt_i="16428" txt_f="16435">=0.18; </offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="26625" xml_f="26641" txt_i="16435" txt_f="16451">Figures 2C and D</offsets></xref><offsets xml_i="26648" xml_f="26727" txt_i="16451" txt_f="16530">). The changes of PDGF-AA and PDGF-BB on individual patient level are shown in </offsets><xref ref-type="supplementary-material" rid="sup1"><offsets xml_i="26778" xml_f="26801" txt_i="16530" txt_f="16553">Supplementary Figure e3</offsets></xref><offsets xml_i="26808" xml_f="26809" txt_i="16553" txt_f="16554">.</offsets></p></sec><sec><title><offsets xml_i="26831" xml_f="26883" txt_i="16556" txt_f="16608">Changes in tissue markers in response to bevacizumab</offsets></title><p><offsets xml_i="26894" xml_f="27086" txt_i="16609" txt_f="16801">Histological data on all patients demonstrated that a single dose of bevacizumab induced a significant but small decrease in the MVD, more specifically in the proportion of vessels covered by </offsets><italic><offsets xml_i="27094" xml_f="27095" txt_i="16801" txt_f="16802">α</offsets></italic><offsets xml_i="27104" xml_f="27173" txt_i="16802" txt_f="16871">-SMA-positive pericytes. The MVD shifted from 74 blood vessels per mm</offsets><sup><offsets xml_i="27178" xml_f="27179" txt_i="16871" txt_f="16872">2</offsets></sup><offsets xml_i="27185" xml_f="27214" txt_i="16872" txt_f="16901"> (36–126 blood vessels per mm</offsets><sup><offsets xml_i="27219" xml_f="27220" txt_i="16901" txt_f="16902">2</offsets></sup><offsets xml_i="27226" xml_f="27254" txt_i="16902" txt_f="16930">) to 62 blood vessels per mm</offsets><sup><offsets xml_i="27259" xml_f="27260" txt_i="16930" txt_f="16931">2</offsets></sup><offsets xml_i="27266" xml_f="27295" txt_i="16931" txt_f="16960"> (22–151 blood vessels per mm</offsets><sup><offsets xml_i="27300" xml_f="27301" txt_i="16960" txt_f="16961">2</offsets></sup><offsets xml_i="27307" xml_f="27309" txt_i="16961" txt_f="16963">; </offsets><italic><offsets xml_i="27317" xml_f="27318" txt_i="16963" txt_f="16964">P</offsets></italic><offsets xml_i="27327" xml_f="27447" txt_i="16964" txt_f="17084">=0.02) and the proportion of mature vessels declined from 87% (20–98%) before treatment to 73% (35–91%) afterwards (T1; </offsets><italic><offsets xml_i="27455" xml_f="27456" txt_i="17084" txt_f="17085">P</offsets></italic><offsets xml_i="27465" xml_f="27553" txt_i="17085" txt_f="17170">&lt;0.0001). The decrease in pericyte-covered blood vessels was similar in both groups (</offsets><xref ref-type="fig" rid="fig3"><offsets xml_i="27585" xml_f="27601" txt_i="17170" txt_f="17186">Figures 3A and B</offsets></xref><offsets xml_i="27608" xml_f="27715" txt_i="17186" txt_f="17293">). However, the effect on the MVD was more pronounced in the responders (from 71 to 53 blood vessels per mm</offsets><sup><offsets xml_i="27720" xml_f="27721" txt_i="17293" txt_f="17294">2</offsets></sup><offsets xml_i="27727" xml_f="27729" txt_i="17294" txt_f="17296">; </offsets><italic><offsets xml_i="27737" xml_f="27738" txt_i="17296" txt_f="17297">P</offsets></italic><offsets xml_i="27747" xml_f="27816" txt_i="17297" txt_f="17366">=0.11) than in the non-responders (from 74 to 64 blood vessels per mm</offsets><sup><offsets xml_i="27821" xml_f="27822" txt_i="17366" txt_f="17367">2</offsets></sup><offsets xml_i="27828" xml_f="27830" txt_i="17367" txt_f="17369">; </offsets><italic><offsets xml_i="27838" xml_f="27839" txt_i="17369" txt_f="17370">P</offsets></italic><offsets xml_i="27848" xml_f="27883" txt_i="17370" txt_f="17405">=0.20) although not significantly (</offsets><italic><offsets xml_i="27891" xml_f="27892" txt_i="17405" txt_f="17406">P</offsets></italic><offsets xml_i="27901" xml_f="27908" txt_i="17406" txt_f="17413">=0.91; </offsets><xref ref-type="fig" rid="fig3"><offsets xml_i="27940" xml_f="27956" txt_i="17413" txt_f="17429">Figures 3C and D</offsets></xref><offsets xml_i="27963" xml_f="27965" txt_i="17429" txt_f="17431">).</offsets></p><p><offsets xml_i="27972" xml_f="28099" txt_i="17432" txt_f="17559">Hypoxia, measured by CA-IX expression, showed a small but nonsignificant increase during bevacizumab treatment from 10 to 20% (</offsets><italic><offsets xml_i="28107" xml_f="28108" txt_i="17559" txt_f="17560">P</offsets></italic><offsets xml_i="28117" xml_f="28186" txt_i="17560" txt_f="17629">=0.08). This increase was more pronounced, although not significant (</offsets><italic><offsets xml_i="28194" xml_f="28195" txt_i="17629" txt_f="17630">P</offsets></italic><offsets xml_i="28204" xml_f="28246" txt_i="17630" txt_f="17672">=0.18), in the responders (from 13 to 38% </offsets><italic><offsets xml_i="28254" xml_f="28255" txt_i="17672" txt_f="17673">P</offsets></italic><offsets xml_i="28264" xml_f="28321" txt_i="17673" txt_f="17730">=0.15) in contrast to the non-responders (from 10 to 11% </offsets><italic><offsets xml_i="28329" xml_f="28330" txt_i="17730" txt_f="17731">P</offsets></italic><offsets xml_i="28339" xml_f="28346" txt_i="17731" txt_f="17738">=0.41; </offsets><xref ref-type="fig" rid="fig3"><offsets xml_i="28378" xml_f="28394" txt_i="17738" txt_f="17754">Figures 3E and F</offsets></xref><offsets xml_i="28401" xml_f="28475" txt_i="17754" txt_f="17828">). The changes in tissue markers on individual patient level are shown in </offsets><xref ref-type="supplementary-material" rid="sup1"><offsets xml_i="28526" xml_f="28549" txt_i="17828" txt_f="17851">Supplementary Figure e4</offsets></xref><offsets xml_i="28556" xml_f="28557" txt_i="17851" txt_f="17852">.</offsets></p></sec><sec><title><offsets xml_i="28579" xml_f="28615" txt_i="17854" txt_f="17890">Exploration of prognostic biomarkers</offsets></title><p><offsets xml_i="28626" xml_f="28893" txt_i="17891" txt_f="18158">In order to explore prognostic biomarkers, the genes and proteins affected by bevacizumab were correlated with the pathological response of the patients and the Dworak regression grade. However, as the number of patients in some Dworak-response groups was too small (</offsets><xref rid="tbl1" ref-type="table"><offsets xml_i="28927" xml_f="28934" txt_i="18158" txt_f="18165">Table 1</offsets></xref><offsets xml_i="28941" xml_f="29189" txt_i="18165" txt_f="18413">), no relevant statistical data could be obtained for this response parameter. We evaluated the expression at baseline (for selection of patients before start of treatment) and the expression after one (T1) or two (T2) loading doses of bevacizumab.</offsets></p></sec><sec><title><offsets xml_i="29211" xml_f="29233" txt_i="18415" txt_f="18437">Biomarkers at baseline</offsets></title><p><offsets xml_i="29244" xml_f="29322" txt_i="18438" txt_f="18516">When comparing gene expression between baseline tumour and mucosa samples (T0 </offsets><italic><offsets xml_i="29330" xml_f="29332" txt_i="18516" txt_f="18518">vs</offsets></italic><offsets xml_i="29341" xml_f="29479" txt_i="18518" txt_f="18656"> M), 1585 and 1542 genes were found differentially expressed in responders and non-responders, respectively (fold change of ⩾1 or ⩽−1 and </offsets><italic><offsets xml_i="29487" xml_f="29488" txt_i="18656" txt_f="18657">P</offsets></italic><offsets xml_i="29497" xml_f="29696" txt_i="18657" txt_f="18853">&lt;0.001). Using these genes, 41 and 30 GO biological processes were enriched in responders and non-responders, respectively. The unique biological processes for each patient group are presented in </offsets><xref rid="tbl3" ref-type="table"><offsets xml_i="29730" xml_f="29737" txt_i="18853" txt_f="18860">Table 3</offsets></xref><offsets xml_i="29744" xml_f="30363" txt_i="18860" txt_f="19479">. Significant GO processes in the responding patients include migratory pathways such as wound healing, cell motion and motility, and pathways involved in cell proliferation such as regulation of mitosis, nuclear division and spindle organisation, which might reflect a good response to oxaliplatin. Also processes related to angiogenesis such as vasculature development, blood vessel development and blood vessel morphogenesis were enriched at baseline in responding patients but not in the non-responding patients. This could suggest that these processes show an intrinsic sensitive profile for bevacizumab treatment.</offsets></p></sec><sec><title><offsets xml_i="30385" xml_f="30424" txt_i="19481" txt_f="19520">Biomarkers during bevacizumab treatment</offsets></title><p><offsets xml_i="30435" xml_f="30529" txt_i="19521" txt_f="19615">After one loading dose of bevacizumab, patients obtaining a pCR had significant lower tumoral </offsets><italic><offsets xml_i="30537" xml_f="30542" txt_i="19615" txt_f="19620">PDGFA</offsets></italic><offsets xml_i="30551" xml_f="30604" txt_i="19620" txt_f="19673"> expression compared with the ones without pCR (6.19 </offsets><italic><offsets xml_i="30612" xml_f="30614" txt_i="19673" txt_f="19675">vs</offsets></italic><offsets xml_i="30623" xml_f="30630" txt_i="19675" txt_f="19682"> 6.93; </offsets><italic><offsets xml_i="30638" xml_f="30639" txt_i="19682" txt_f="19683">P</offsets></italic><offsets xml_i="30648" xml_f="30697" txt_i="19683" txt_f="19732">=0.04), less pericyte-covered blood vessels (64% </offsets><italic><offsets xml_i="30705" xml_f="30707" txt_i="19732" txt_f="19734">vs</offsets></italic><offsets xml_i="30716" xml_f="30721" txt_i="19734" txt_f="19739"> 77% </offsets><italic><offsets xml_i="30729" xml_f="30730" txt_i="19739" txt_f="19740">P</offsets></italic><offsets xml_i="30739" xml_f="30781" txt_i="19740" txt_f="19782">=0.02) and a higher CA-IX expression (38% </offsets><italic><offsets xml_i="30789" xml_f="30791" txt_i="19782" txt_f="19784">vs</offsets></italic><offsets xml_i="30800" xml_f="30805" txt_i="19784" txt_f="19789"> 11% </offsets><italic><offsets xml_i="30813" xml_f="30814" txt_i="19789" txt_f="19790">P</offsets></italic><offsets xml_i="30823" xml_f="30831" txt_i="19790" txt_f="19798">=0.004; </offsets><xref ref-type="fig" rid="fig4"><offsets xml_i="30863" xml_f="30875" txt_i="19798" txt_f="19810">Figures 4A–C</offsets></xref><offsets xml_i="30882" xml_f="30884" txt_i="19810" txt_f="19812">).</offsets></p><p><offsets xml_i="30891" xml_f="30986" txt_i="19813" txt_f="19908">After two doses of bevacizumab, responders had significant lower levels of PDGF-BB (206.2 pg ml</offsets><sup><offsets xml_i="30991" xml_f="30993" txt_i="19908" txt_f="19910">−1</offsets></sup><offsets xml_i="30999" xml_f="31046" txt_i="19910" txt_f="19957">) compared with the non-responders (343.1 pg ml</offsets><sup><offsets xml_i="31051" xml_f="31053" txt_i="19957" txt_f="19959">−1</offsets></sup><offsets xml_i="31059" xml_f="31061" txt_i="19959" txt_f="19961">; </offsets><italic><offsets xml_i="31069" xml_f="31070" txt_i="19961" txt_f="19962">P</offsets></italic><offsets xml_i="31079" xml_f="31086" txt_i="19962" txt_f="19969">=0.04; </offsets><xref ref-type="fig" rid="fig4"><offsets xml_i="31118" xml_f="31127" txt_i="19969" txt_f="19978">Figure 4D</offsets></xref><offsets xml_i="31134" xml_f="31136" txt_i="19978" txt_f="19980">).</offsets></p><p><offsets xml_i="31143" xml_f="31168" txt_i="19981" txt_f="20006">These data indicate that </offsets><italic><offsets xml_i="31176" xml_f="31181" txt_i="20006" txt_f="20011">PDGFA</offsets></italic><offsets xml_i="31190" xml_f="31295" txt_i="20011" txt_f="20116">, PDGF-BB, CA-IX and pericyte-covered blood vessels might be used as prognostic markers after validation.</offsets></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="31345" xml_f="31355" txt_i="20119" txt_f="20129">Discussion</offsets></title><p><offsets xml_i="31366" xml_f="31733" txt_i="20130" txt_f="20497">Investigating the effect of anti-VEGF therapy, radiotherapy and chemotherapy in clinical trials has often been hampered by the inability to perform serial tumour biopsies in patients, thereby preventing direct analysis of molecular and genetic changes after anti-angiogenic therapies. With the design of this study, we had the unique opportunity to investigate the mo</offsets></p><sec><title><offsets xml_i="31749" xml_f="31797" txt_i="20498" txt_f="20546">Changes induced by bevacizumab in AXEBeam trial </offsets><italic><offsets xml_i="31805" xml_f="31807" txt_i="20546" txt_f="20548">vs</offsets></italic><offsets xml_i="31816" xml_f="31825" txt_i="20548" txt_f="20557"> Willett </offsets><italic><offsets xml_i="31833" xml_f="31838" txt_i="20557" txt_f="20562">et al</offsets></italic></title><p><offsets xml_i="31858" xml_f="31970" txt_i="20563" txt_f="20675">Until now it is still not completely clear which effect bevacizumab has on tumours from rectal cancer patients. </offsets><xref ref-type="bibr" rid="bib67"><offsets xml_i="32004" xml_f="32012" txt_i="20675" txt_f="20683">Willett </offsets><italic><offsets xml_i="32020" xml_f="32025" txt_i="20683" txt_f="20688">et al</offsets></italic><offsets xml_i="32034" xml_f="32040" txt_i="20688" txt_f="20694"> (2004</offsets></xref><offsets xml_i="32047" xml_f="32049" txt_i="20694" txt_f="20696">, </offsets><xref ref-type="bibr" rid="bib68"><offsets xml_i="32083" xml_f="32088" txt_i="20696" txt_f="20701">2005)</offsets></xref><offsets xml_i="32095" xml_f="32218" txt_i="20701" txt_f="20824"> measured molecular, cellular and physiological markers before treatment and 2 weeks after one dose of bevacizumab (5 mg kg</offsets><sup><offsets xml_i="32223" xml_f="32225" txt_i="20824" txt_f="20826">−1</offsets></sup><offsets xml_i="32231" xml_f="32320" txt_i="20826" txt_f="20915">) on six patients from their phase I trial and on 32 patients from their phase II trial (</offsets><xref ref-type="bibr" rid="bib70"><offsets xml_i="32354" xml_f="32362" txt_i="20915" txt_f="20923">Willett </offsets><italic><offsets xml_i="32370" xml_f="32375" txt_i="20923" txt_f="20928">et al</offsets></italic><offsets xml_i="32384" xml_f="32390" txt_i="20928" txt_f="20934">, 2009</offsets></xref><offsets xml_i="32397" xml_f="32454" txt_i="20934" txt_f="20991">), in accordance with the setup of the AXEBeam trial. In </offsets><xref rid="tbl4" ref-type="table"><offsets xml_i="32488" xml_f="32495" txt_i="20991" txt_f="20998">Table 4</offsets></xref><offsets xml_i="32502" xml_f="32632" txt_i="20998" txt_f="21128">, the analysed parameters are listed, and alterations observed after bevacizumab monotherapy are compared between the trials from </offsets><xref ref-type="bibr" rid="bib67"><offsets xml_i="32666" xml_f="32674" txt_i="21128" txt_f="21136">Willett </offsets><italic><offsets xml_i="32682" xml_f="32687" txt_i="21136" txt_f="21141">et al</offsets></italic><offsets xml_i="32696" xml_f="32702" txt_i="21141" txt_f="21147"> (2004</offsets></xref><offsets xml_i="32709" xml_f="32711" txt_i="21147" txt_f="21149">, </offsets><xref ref-type="bibr" rid="bib68"><offsets xml_i="32745" xml_f="32750" txt_i="21149" txt_f="21154">2009)</offsets></xref><offsets xml_i="32757" xml_f="32780" txt_i="21154" txt_f="21177"> and the AXEBeam trial.</offsets></p><p><offsets xml_i="32787" xml_f="32797" txt_i="21178" txt_f="21188">Data from </offsets><xref ref-type="bibr" rid="bib67"><offsets xml_i="32831" xml_f="32839" txt_i="21188" txt_f="21196">Willett </offsets><italic><offsets xml_i="32847" xml_f="32852" txt_i="21196" txt_f="21201">et al</offsets></italic><offsets xml_i="32861" xml_f="32867" txt_i="21201" txt_f="21207"> (2004</offsets></xref><offsets xml_i="32874" xml_f="32876" txt_i="21207" txt_f="21209">, </offsets><xref ref-type="bibr" rid="bib68"><offsets xml_i="32910" xml_f="32915" txt_i="21209" txt_f="21214">2009)</offsets></xref><offsets xml_i="32922" xml_f="33753" txt_i="21214" txt_f="22045"> demonstrated antivascular and vascular normalising effects. The antivascular effects, illustrated by a decrease in blood flow, blood volume and MVD, were confirmed by our study with a decrease in MVD. The normalisation effects, which are suggested by a decrease in IFP, less angiopoitein-2-positive blood vessels, higher tumour cell proliferation and an increase in α-SMA coverage, were not observed in the AXEBeam trial. In contrast, we observed a decrease in α-SMA coverage, a slight increase in hypoxia and a decrease in tumour cell proliferation. Bevacizumab was found to stimulate an increase of total circulating VEGF in all studies. However, it is believed that no reliable measurement can be performed once patients have been dosed with bevacizumab, as the majority of VEGF molecules are antibody bound and thus inactive (</offsets><xref ref-type="bibr" rid="bib46"><offsets xml_i="33787" xml_f="33796" txt_i="22045" txt_f="22054">Loupakis </offsets><italic><offsets xml_i="33804" xml_f="33809" txt_i="22054" txt_f="22059">et al</offsets></italic><offsets xml_i="33818" xml_f="33824" txt_i="22059" txt_f="22065">, 2007</offsets></xref><offsets xml_i="33831" xml_f="33833" txt_i="22065" txt_f="22067">; </offsets><xref ref-type="bibr" rid="bib9"><offsets xml_i="33866" xml_f="33875" txt_i="22067" txt_f="22076">Brostjan </offsets><italic><offsets xml_i="33883" xml_f="33888" txt_i="22076" txt_f="22081">et al</offsets></italic><offsets xml_i="33897" xml_f="33903" txt_i="22081" txt_f="22087">, 2008</offsets></xref><offsets xml_i="33910" xml_f="34002" txt_i="22087" txt_f="22179">). In conclusion, the effects of bevacizumab do not seem as straightforward as presented by </offsets><xref ref-type="bibr" rid="bib67"><offsets xml_i="34036" xml_f="34044" txt_i="22179" txt_f="22187">Willett </offsets><italic><offsets xml_i="34052" xml_f="34057" txt_i="22187" txt_f="22192">et al</offsets></italic><offsets xml_i="34066" xml_f="34072" txt_i="22192" txt_f="22198"> (2004</offsets></xref><offsets xml_i="34079" xml_f="34081" txt_i="22198" txt_f="22200">, </offsets><xref ref-type="bibr" rid="bib68"><offsets xml_i="34115" xml_f="34120" txt_i="22200" txt_f="22205">2009)</offsets></xref><offsets xml_i="34127" xml_f="34254" txt_i="22205" txt_f="22332"> and the normalisation hypothesis. To fully unravel the working mechanism of bevacizumab, further molecular research is needed.</offsets></p></sec><sec><title><offsets xml_i="34276" xml_f="34314" txt_i="22334" txt_f="22372">Angiogenic gene profiling as biomarker</offsets></title><p><offsets xml_i="34325" xml_f="35034" txt_i="22373" txt_f="23082">Given the low power of the study, we performed a gene group analysis that might give us more information about changes in response to treatment compared with an analysis at individual gene level. Exploring differentially expressed genes within a biological context defined by GO processes between responding and non-responding patients might give clues about relevant processes for prognosis that would be difficult to identify when evaluating differential expression of individual genes. The multiple comparison error is more pronounced for the individual gene analysis because there are much more individual genes than GO themes. Nevertheless, we have to be aware of limitations inherent to this technique (</offsets><xref ref-type="bibr" rid="bib37"><offsets xml_i="35068" xml_f="35093" txt_i="23082" txt_f="23107">Khatri and Draghici, 2005</offsets></xref><offsets xml_i="35100" xml_f="35102" txt_i="23107" txt_f="23109">).</offsets></p><p><offsets xml_i="35109" xml_f="35667" txt_i="23110" txt_f="23668">Already before start of treatment, our gene expression analysis of the tumours revealed distinct intrinsic characteristics between patients which after treatment showed a pCR or no pCR. First, tumours from responding patients showed to be more highly correlated to angiogenesis, hypothesising the notion that those tumours may be upfront more susceptible to anti-angiogenic treatment than tumours without an angiogenic profile. This is supported by earlier data that showed that vatalanib only has anti-angiogenic effect when the VEGFR pathway is activated (</offsets><xref ref-type="bibr" rid="bib25"><offsets xml_i="35701" xml_f="35716" txt_i="23668" txt_f="23683">Giatromanolaki </offsets><italic><offsets xml_i="35724" xml_f="35729" txt_i="23683" txt_f="23688">et al</offsets></italic><offsets xml_i="35738" xml_f="35744" txt_i="23688" txt_f="23694">, 2012</offsets></xref><offsets xml_i="35751" xml_f="35883" txt_i="23694" txt_f="23826">). Different groups have also shown that response to VEGR inhibitors can be predicted based on a set of angiogenesis-related genes (</offsets><xref ref-type="bibr" rid="bib64"><offsets xml_i="35917" xml_f="35926" txt_i="23826" txt_f="23835">Watanabe </offsets><italic><offsets xml_i="35934" xml_f="35939" txt_i="23835" txt_f="23840">et al</offsets></italic><offsets xml_i="35948" xml_f="35954" txt_i="23840" txt_f="23846">, 2011</offsets></xref><offsets xml_i="35961" xml_f="35963" txt_i="23846" txt_f="23848">; </offsets><xref ref-type="bibr" rid="bib71"><offsets xml_i="35997" xml_f="36004" txt_i="23848" txt_f="23855">Wilson </offsets><italic><offsets xml_i="36012" xml_f="36017" txt_i="23855" txt_f="23860">et al</offsets></italic><offsets xml_i="36026" xml_f="36032" txt_i="23860" txt_f="23866">, 2012</offsets></xref><offsets xml_i="36039" xml_f="36041" txt_i="23866" txt_f="23868">; </offsets><xref ref-type="bibr" rid="bib8"><offsets xml_i="36074" xml_f="36081" txt_i="23868" txt_f="23875">Brauer </offsets><italic><offsets xml_i="36089" xml_f="36094" txt_i="23875" txt_f="23880">et al</offsets></italic><offsets xml_i="36103" xml_f="36109" txt_i="23880" txt_f="23886">, 2013</offsets></xref><offsets xml_i="36116" xml_f="36118" txt_i="23886" txt_f="23888">).</offsets></p><p><offsets xml_i="36125" xml_f="36525" txt_i="23889" txt_f="24289">Moreover, only in those responding tumours with an angiogenic phenotype, an alteration was observed after one bevacizumab dosage in angiogenesis-related GO processes, derived from nine altered genes. These angiogenic-related changes possibly indicate an effect of bevacizumab, as no biological processes were found in non-responding tumours to be influenced by one dose of bevacizumab. Consistently, </offsets><xref ref-type="bibr" rid="bib8"><offsets xml_i="36558" xml_f="36565" txt_i="24289" txt_f="24296">Brauer </offsets><italic><offsets xml_i="36573" xml_f="36578" txt_i="24296" txt_f="24301">et al</offsets></italic><offsets xml_i="36587" xml_f="36594" txt_i="24301" txt_f="24308"> (2013)</offsets></xref><offsets xml_i="36601" xml_f="36826" txt_i="24308" txt_f="24533"> performed microarray analysis on tumours from anti-VEGF-treated mice, revealing a decreased expression of known endothelial-specific genes and genes implicated in blood vessel development in response to anti-VEGF treatment. </offsets><xref ref-type="bibr" rid="bib39"><offsets xml_i="36860" xml_f="36872" txt_i="24533" txt_f="24545">Koukourakis </offsets><italic><offsets xml_i="36880" xml_f="36885" txt_i="24545" txt_f="24550">et al</offsets></italic><offsets xml_i="36894" xml_f="36901" txt_i="24550" txt_f="24557"> (2009)</offsets></xref><offsets xml_i="36908" xml_f="37034" txt_i="24557" txt_f="24683"> found a direct effect of bevacizumab on specific cancer cell pathways but not on hypoxia target genes or endothelial markers.</offsets></p><p><offsets xml_i="37041" xml_f="37117" txt_i="24684" txt_f="24760">Among all nine genes responsible for the altered angiogenic processes, only </offsets><italic><offsets xml_i="37125" xml_f="37130" txt_i="24760" txt_f="24765">PDGFA</offsets></italic><offsets xml_i="37139" xml_f="37193" txt_i="24765" txt_f="24819"> seems to be prognostic at the individual gene level. </offsets><italic><offsets xml_i="37201" xml_f="37206" txt_i="24819" txt_f="24824">PDGFA</offsets></italic><offsets xml_i="37215" xml_f="37406" txt_i="24824" txt_f="25015"> expression decreased in response to one dose of bevacizumab in responders but not in non-responders. This makes it a possible prognostic genetic maker, with responding patients having lower </offsets><italic><offsets xml_i="37414" xml_f="37419" txt_i="25015" txt_f="25020">PDGFA</offsets></italic><offsets xml_i="37428" xml_f="37499" txt_i="25020" txt_f="25091"> levels after one dose of bevacizumab compared with the non-responders.</offsets></p><p><offsets xml_i="37506" xml_f="37867" txt_i="25092" txt_f="25453">Next to the aniogenic processes, gene expression analysis at baseline also revealed pathways in responder patients that might be attributed to the effect of oxaliplatin. It is know that this platinum compound exerts its effect through inhibition of DNA synthesis by preventing DNA replication and transcription. But it might also affect cell cycle progression (</offsets><xref ref-type="bibr" rid="bib63"><offsets xml_i="37901" xml_f="37908" txt_i="25453" txt_f="25460">Voland </offsets><italic><offsets xml_i="37916" xml_f="37921" txt_i="25460" txt_f="25465">et al</offsets></italic><offsets xml_i="37930" xml_f="37936" txt_i="25465" txt_f="25471">, 2006</offsets></xref><offsets xml_i="37943" xml_f="37966" txt_i="25471" txt_f="25494">), migration of cells (</offsets><xref ref-type="bibr" rid="bib22"><offsets xml_i="38000" xml_f="38005" txt_i="25494" txt_f="25499">Gaur </offsets><italic><offsets xml_i="38013" xml_f="38018" txt_i="25499" txt_f="25504">et al</offsets></italic><offsets xml_i="38027" xml_f="38033" txt_i="25504" txt_f="25510">, 2014</offsets></xref><offsets xml_i="38040" xml_f="38080" txt_i="25510" txt_f="25550">) and spindle formation during mitosis (</offsets><xref ref-type="bibr" rid="bib58"><offsets xml_i="38114" xml_f="38119" txt_i="25550" txt_f="25555">Sohn </offsets><italic><offsets xml_i="38127" xml_f="38132" txt_i="25555" txt_f="25560">et al</offsets></italic><offsets xml_i="38141" xml_f="38147" txt_i="25560" txt_f="25566">, 2010</offsets></xref><offsets xml_i="38154" xml_f="38673" txt_i="25566" txt_f="26085">). As in our study, patients receiving oxaliplatin in their chemotherapy regimen (arm A) show a higher pCR rate, those enriched biological processes in responding patients might reflect a higher sensitivity to oxaliplatin, rather than to bevacizumab. The GO category for spindle organisation was reported before to separate responders from non-responders at baseline in patients with breast cancer treated with bevacizumab and chemotherapy, but was hypothesised to be more likely relevant to the response to docetaxel (</offsets><xref ref-type="bibr" rid="bib73"><offsets xml_i="38707" xml_f="38712" txt_i="26085" txt_f="26090">Yang </offsets><italic><offsets xml_i="38720" xml_f="38725" txt_i="26090" txt_f="26095">et al</offsets></italic><offsets xml_i="38734" xml_f="38740" txt_i="26095" txt_f="26101">, 2008</offsets></xref><offsets xml_i="38747" xml_f="38749" txt_i="26101" txt_f="26103">).</offsets></p></sec><sec><title><offsets xml_i="38771" xml_f="38796" txt_i="26105" txt_f="26130">Role of tissue biomarkers</offsets></title><p><offsets xml_i="38807" xml_f="39079" txt_i="26131" txt_f="26403">Consistent with the gene expression data, bevacizumab modified certain angiogenic parameters in tumoral tissue that were more explicit in responders. Both the decrease in MVD and increase in hypoxia were more pronounced in responding patients compared with non-responders.</offsets></p><p><offsets xml_i="39086" xml_f="39384" txt_i="26404" txt_f="26702">When looking for associations, patients with a pCR had less pericyte-covered blood vessels and more hypoxia within the tumour after one dose of bevacizumab treatment compared with patients who did not have a pCR, indicating that CA-IX and pericyte-covered blood vessels might be prognostic markers.</offsets></p><p><offsets xml_i="39391" xml_f="39423" txt_i="26703" txt_f="26735">Apart from the decrease in MVD (</offsets><xref ref-type="bibr" rid="bib67"><offsets xml_i="39457" xml_f="39465" txt_i="26735" txt_f="26743">Willett </offsets><italic><offsets xml_i="39473" xml_f="39478" txt_i="26743" txt_f="26748">et al</offsets></italic><offsets xml_i="39487" xml_f="39493" txt_i="26748" txt_f="26754">, 2004</offsets></xref><offsets xml_i="39500" xml_f="39608" txt_i="26754" txt_f="26862">), our observations are in contrast with the literature in which according to the normalisation hypothesis (</offsets><xref ref-type="bibr" rid="bib34"><offsets xml_i="39642" xml_f="39652" txt_i="26862" txt_f="26872">Jain, 2005</offsets></xref><offsets xml_i="39659" xml_f="39742" txt_i="26872" txt_f="26955">), one dose of bevacizumab increased the number of pericyte-covered blood vessels (</offsets><xref ref-type="bibr" rid="bib67"><offsets xml_i="39776" xml_f="39784" txt_i="26955" txt_f="26963">Willett </offsets><italic><offsets xml_i="39792" xml_f="39797" txt_i="26963" txt_f="26968">et al</offsets></italic><offsets xml_i="39806" xml_f="39812" txt_i="26968" txt_f="26974">, 2004</offsets></xref><offsets xml_i="39819" xml_f="39844" txt_i="26974" txt_f="26999">) and decreased hypoxia (</offsets><xref ref-type="bibr" rid="bib33"><offsets xml_i="39878" xml_f="39888" txt_i="26999" txt_f="27009">Jain, 2001</offsets></xref><offsets xml_i="39895" xml_f="39897" txt_i="27009" txt_f="27011">; </offsets><xref ref-type="bibr" rid="bib72"><offsets xml_i="39931" xml_f="39939" txt_i="27011" txt_f="27019">Winkler </offsets><italic><offsets xml_i="39947" xml_f="39952" txt_i="27019" txt_f="27024">et al</offsets></italic><offsets xml_i="39961" xml_f="39967" txt_i="27024" txt_f="27030">, 2004</offsets></xref><offsets xml_i="39974" xml_f="40183" txt_i="27030" txt_f="27239">) leading to an enhanced radiation response and better outcome. Also, lower CA-IX expression was reported to be associated with better clinical outcome in patients treated with bevacizumab-based chemotherapy (</offsets><xref ref-type="bibr" rid="bib52"><offsets xml_i="40217" xml_f="40232" txt_i="27239" txt_f="27254">Sathornsumetee </offsets><italic><offsets xml_i="40240" xml_f="40245" txt_i="27254" txt_f="27259">et al</offsets></italic><offsets xml_i="40254" xml_f="40260" txt_i="27259" txt_f="27265">, 2008</offsets></xref><offsets xml_i="40267" xml_f="40269" txt_i="27265" txt_f="27267">; </offsets><xref ref-type="bibr" rid="bib28"><offsets xml_i="40303" xml_f="40308" txt_i="27267" txt_f="27272">Hong </offsets><italic><offsets xml_i="40316" xml_f="40321" txt_i="27272" txt_f="27277">et al</offsets></italic><offsets xml_i="40330" xml_f="40336" txt_i="27277" txt_f="27283">, 2009</offsets></xref><offsets xml_i="40343" xml_f="40498" txt_i="27283" txt_f="27438">). According to other reports pericyte content of CRC was not linked to treatment outcome in metastatic CRC patients under bevacizumab-containing therapy (</offsets><xref ref-type="bibr" rid="bib26"><offsets xml_i="40532" xml_f="40538" txt_i="27438" txt_f="27444">Goede </offsets><italic><offsets xml_i="40546" xml_f="40551" txt_i="27444" txt_f="27449">et al</offsets></italic><offsets xml_i="40560" xml_f="40566" txt_i="27449" txt_f="27455">, 2010</offsets></xref><offsets xml_i="40573" xml_f="40889" txt_i="27455" txt_f="27771">). Contradicting results between our data and literature, however, could be related to small differences in the protocol and moment of sample collection, as normalisation is reported to be transient and context dependent. But then again, as VEGF facilitates the process of pericyte recruitment to endothelial cells (</offsets><xref ref-type="bibr" rid="bib5"><offsets xml_i="40922" xml_f="40931" txt_i="27771" txt_f="27780">Benjamin </offsets><italic><offsets xml_i="40939" xml_f="40944" txt_i="27780" txt_f="27785">et al</offsets></italic><offsets xml_i="40953" xml_f="40959" txt_i="27785" txt_f="27791">, 1998</offsets></xref><offsets xml_i="40966" xml_f="41290" txt_i="27791" txt_f="28115">), one could also hypothesise that blocking VEGF can result in less pericyte recruitment and coverage. When following this reasoning, the observed decrease in pericyte coverage after bevacizumab treatment in our study seems logic in contrast to the normalisation hypothesis were an increase in pericyte coverage is expected.</offsets></p><p><offsets xml_i="41297" xml_f="41508" txt_i="28116" txt_f="28327">The complex influence of all angiogenic regulators is believed to be summarised by the MVD. Although MVD has been used before as a surrogate marker of angiogenesis in CRC and has been associated with prognosis (</offsets><xref ref-type="bibr" rid="bib19"><offsets xml_i="41542" xml_f="41548" txt_i="28327" txt_f="28333">Frank </offsets><italic><offsets xml_i="41556" xml_f="41561" txt_i="28333" txt_f="28338">et al</offsets></italic><offsets xml_i="41570" xml_f="41576" txt_i="28338" txt_f="28344">, 1995</offsets></xref><offsets xml_i="41583" xml_f="41585" txt_i="28344" txt_f="28346">; </offsets><xref ref-type="bibr" rid="bib74"><offsets xml_i="41619" xml_f="41625" txt_i="28346" txt_f="28352">Zheng </offsets><italic><offsets xml_i="41633" xml_f="41638" txt_i="28352" txt_f="28357">et al</offsets></italic><offsets xml_i="41647" xml_f="41653" txt_i="28357" txt_f="28363">, 2003</offsets></xref><offsets xml_i="41660" xml_f="41662" txt_i="28363" txt_f="28365">; </offsets><xref ref-type="bibr" rid="bib20"><offsets xml_i="41696" xml_f="41704" txt_i="28365" txt_f="28373">Galizia </offsets><italic><offsets xml_i="41712" xml_f="41717" txt_i="28373" txt_f="28378">et al</offsets></italic><offsets xml_i="41726" xml_f="41732" txt_i="28378" txt_f="28384">, 2004</offsets></xref><offsets xml_i="41739" xml_f="41938" txt_i="28384" txt_f="28583">), the significance of MVD in evaluating the response to anti-angiogenic agents remains unclear. Although some reports found a positive correlation between MVD and benefit from bevacizumab plus CRT (</offsets><xref ref-type="bibr" rid="bib16"><offsets xml_i="41972" xml_f="41982" txt_i="28583" txt_f="28593">Foernzler </offsets><italic><offsets xml_i="41990" xml_f="41995" txt_i="28593" txt_f="28598">et al</offsets></italic><offsets xml_i="42004" xml_f="42010" txt_i="28598" txt_f="28604">, 2010</offsets></xref><offsets xml_i="42017" xml_f="42019" txt_i="28604" txt_f="28606">; </offsets><xref ref-type="bibr" rid="bib21"><offsets xml_i="42053" xml_f="42063" txt_i="28606" txt_f="28616">Gasparini </offsets><italic><offsets xml_i="42071" xml_f="42076" txt_i="28616" txt_f="28621">et al</offsets></italic><offsets xml_i="42085" xml_f="42091" txt_i="28621" txt_f="28627">, 2012</offsets></xref><offsets xml_i="42098" xml_f="42124" txt_i="28627" txt_f="28653">), we and others did not (</offsets><xref ref-type="bibr" rid="bib35"><offsets xml_i="42158" xml_f="42163" txt_i="28653" txt_f="28658">Jubb </offsets><italic><offsets xml_i="42171" xml_f="42176" txt_i="28658" txt_f="28663">et al</offsets></italic><offsets xml_i="42185" xml_f="42191" txt_i="28663" txt_f="28669">, 2006</offsets></xref><offsets xml_i="42198" xml_f="42734" txt_i="28669" txt_f="29205">). Nevertheless, although we could not find a correlation between MVD and response, it is remarkable that MVD decreased, although not significantly, after bevacizumab delivery in responding patients but not in non-responders. As mentioned before, the fraction of immature vessels provided additional information in our study, illustrating that assessing pericyte recruitment can probably more realistically indicate the angiogenic status of tumour vasculature compared with MVD counting that reflects only the presence of blood vessels.</offsets></p><p><offsets xml_i="42741" xml_f="43019" txt_i="29206" txt_f="29484">Although we identified in responders several significant GO processes related to cell proliferation that are most likely relevant to the response to oxaliplatin, no differences were observed in Ki67 and cleaved PARP levels between responders and non-responders (data not shown).</offsets></p></sec><sec><title><offsets xml_i="43041" xml_f="43085" txt_i="29486" txt_f="29530">Angiogenic circulating markers as biomarkers</offsets></title><p><offsets xml_i="43096" xml_f="43237" txt_i="29531" txt_f="29672">Circulating PDGF-AA showed a more pronounced decrease in responders after two doses of bevacizumab (T2), which was also reflected in tumoral </offsets><italic><offsets xml_i="43245" xml_f="43250" txt_i="29672" txt_f="29677">PDGFA</offsets></italic><offsets xml_i="43259" xml_f="43647" txt_i="29677" txt_f="30065"> expression levels. Bevacizumab treatment caused also a large decrease between T0 and T2 in circulating PDGF-BB levels in patients with a pCR, which was not observed in non-responders. As a result, responders displayed, after two doses of bevacizumab, lower PDGF-BB levels in their blood compared with the non-responders, indicating that this protein might be used as a prognostic marker.</offsets></p><p><offsets xml_i="43654" xml_f="43825" txt_i="30066" txt_f="30237">However, combined chemoirradiation with or without multi-tyrosine kinase inhibitors against VEGF has also been shown to decrease circulating levels of PDGF-AA or PDGF-BB (</offsets><xref ref-type="bibr" rid="bib47"><offsets xml_i="43859" xml_f="43865" txt_i="30237" txt_f="30243">Loven </offsets><italic><offsets xml_i="43873" xml_f="43878" txt_i="30243" txt_f="30248">et al</offsets></italic><offsets xml_i="43887" xml_f="43893" txt_i="30248" txt_f="30254">, 2008</offsets></xref><offsets xml_i="43900" xml_f="43902" txt_i="30254" txt_f="30256">; </offsets><xref ref-type="bibr" rid="bib32"><offsets xml_i="43936" xml_f="43942" txt_i="30256" txt_f="30262">Inanc </offsets><italic><offsets xml_i="43950" xml_f="43955" txt_i="30262" txt_f="30267">et al</offsets></italic><offsets xml_i="43964" xml_f="43970" txt_i="30267" txt_f="30273">, 2012</offsets></xref><offsets xml_i="43977" xml_f="43979" txt_i="30273" txt_f="30275">; </offsets><xref ref-type="bibr" rid="bib55"><offsets xml_i="44013" xml_f="44018" txt_i="30275" txt_f="30280">Shin </offsets><italic><offsets xml_i="44026" xml_f="44031" txt_i="30280" txt_f="30285">et al</offsets></italic><offsets xml_i="44040" xml_f="44046" txt_i="30285" txt_f="30291">, 2012</offsets></xref><offsets xml_i="44053" xml_f="44210" txt_i="30291" txt_f="30448">). Therefore, as in our study the first cycle of CRT was already started at T2, we have to be aware that the observed decline might be partly due to the CRT.</offsets></p><p><offsets xml_i="44217" xml_f="44577" txt_i="30449" txt_f="30809">The other four markers tested (thrombospondin-1, angiopoietin-2, IL-8 and CYR61) displayed no differences between the two response subgroups upon bevacizumab delivery, and were not found to be associated with pathological response before or after bevacizumab treatment. However, in literature, data indicate a role for some of them in response to bevacizumab (</offsets><xref ref-type="bibr" rid="bib26"><offsets xml_i="44611" xml_f="44617" txt_i="30809" txt_f="30815">Goede </offsets><italic><offsets xml_i="44625" xml_f="44630" txt_i="30815" txt_f="30820">et al</offsets></italic><offsets xml_i="44639" xml_f="44645" txt_i="30820" txt_f="30826">, 2010</offsets></xref><offsets xml_i="44652" xml_f="44654" txt_i="30826" txt_f="30828">; </offsets><xref ref-type="bibr" rid="bib29"><offsets xml_i="44688" xml_f="44694" txt_i="30828" txt_f="30834">Huang </offsets><italic><offsets xml_i="44702" xml_f="44707" txt_i="30834" txt_f="30839">et al</offsets></italic><offsets xml_i="44716" xml_f="44722" txt_i="30839" txt_f="30845">, 2010</offsets></xref><offsets xml_i="44729" xml_f="44731" txt_i="30845" txt_f="30847">; </offsets><xref ref-type="bibr" rid="bib38"><offsets xml_i="44765" xml_f="44772" txt_i="30847" txt_f="30854">Kopetz </offsets><italic><offsets xml_i="44780" xml_f="44785" txt_i="30854" txt_f="30859">et al</offsets></italic><offsets xml_i="44794" xml_f="44800" txt_i="30859" txt_f="30865">, 2010</offsets></xref><offsets xml_i="44807" xml_f="44809" txt_i="30865" txt_f="30867">; </offsets><xref ref-type="bibr" rid="bib45"><offsets xml_i="44843" xml_f="44852" txt_i="30867" txt_f="30876">Loupakis </offsets><italic><offsets xml_i="44860" xml_f="44865" txt_i="30876" txt_f="30881">et al</offsets></italic><offsets xml_i="44874" xml_f="44880" txt_i="30881" txt_f="30887">, 2011</offsets></xref><offsets xml_i="44887" xml_f="44889" txt_i="30887" txt_f="30889">; </offsets><xref ref-type="bibr" rid="bib1"><offsets xml_i="44922" xml_f="44928" txt_i="30889" txt_f="30895">Abajo </offsets><italic><offsets xml_i="44936" xml_f="44941" txt_i="30895" txt_f="30900">et al</offsets></italic><offsets xml_i="44950" xml_f="44956" txt_i="30900" txt_f="30906">, 2012</offsets></xref><offsets xml_i="44963" xml_f="44965" txt_i="30906" txt_f="30908">; </offsets><xref ref-type="bibr" rid="bib44"><offsets xml_i="44999" xml_f="45003" txt_i="30908" txt_f="30912">Liu </offsets><italic><offsets xml_i="45011" xml_f="45016" txt_i="30912" txt_f="30917">et al</offsets></italic><offsets xml_i="45025" xml_f="45031" txt_i="30917" txt_f="30923">, 2013</offsets></xref><offsets xml_i="45038" xml_f="45040" txt_i="30923" txt_f="30925">).</offsets></p></sec><sec><title><offsets xml_i="45062" xml_f="45072" txt_i="30927" txt_f="30937">Hypothesis</offsets></title><p><offsets xml_i="45083" xml_f="45285" txt_i="30938" txt_f="31140">Putting all our data together, we hypothesise that bevacizumab in this clinical trial fulfils a role as inhibitor of new blood vessel formation as it blocks VEGF as facilitator of pericyte recruitment (</offsets><xref ref-type="bibr" rid="bib5"><offsets xml_i="45318" xml_f="45327" txt_i="31140" txt_f="31149">Benjamin </offsets><italic><offsets xml_i="45335" xml_f="45340" txt_i="31149" txt_f="31154">et al</offsets></italic><offsets xml_i="45349" xml_f="45355" txt_i="31154" txt_f="31160">, 1998</offsets></xref><offsets xml_i="45362" xml_f="45679" txt_i="31160" txt_f="31477">). Our data suggest that patients respond better when the tumour has less pericyte-covered blood vessels, leading to destabilisation of the vessels that makes them more susceptible to bevacizumab, resulting in a better response. Pericytes may express VEGF as survival factor for their neighbouring endothelial cells (</offsets><xref ref-type="bibr" rid="bib12"><offsets xml_i="45713" xml_f="45721" txt_i="31477" txt_f="31485">Darland </offsets><italic><offsets xml_i="45729" xml_f="45734" txt_i="31485" txt_f="31490">et al</offsets></italic><offsets xml_i="45743" xml_f="45749" txt_i="31490" txt_f="31496">, 2003</offsets></xref><offsets xml_i="45756" xml_f="45758" txt_i="31496" txt_f="31498">; </offsets><xref ref-type="bibr" rid="bib18"><offsets xml_i="45792" xml_f="45799" txt_i="31498" txt_f="31505">Franco </offsets><italic><offsets xml_i="45807" xml_f="45812" txt_i="31505" txt_f="31510">et al</offsets></italic><offsets xml_i="45821" xml_f="45827" txt_i="31510" txt_f="31516">, 2011</offsets></xref><offsets xml_i="45834" xml_f="46028" txt_i="31516" txt_f="31710">) and provide endothelial cell survival signals. As a consequence, more mature vessels may acquire independence from tumour-secreted VEGF resulting possibly in insensitivity to VEGF withdrawal (</offsets><xref ref-type="bibr" rid="bib15"><offsets xml_i="46062" xml_f="46070" txt_i="31710" txt_f="31718">Evensen </offsets><italic><offsets xml_i="46078" xml_f="46083" txt_i="31718" txt_f="31723">et al</offsets></italic><offsets xml_i="46092" xml_f="46098" txt_i="31723" txt_f="31729">, 2009</offsets></xref><offsets xml_i="46105" xml_f="46107" txt_i="31729" txt_f="31731">; </offsets><xref ref-type="bibr" rid="bib56"><offsets xml_i="46141" xml_f="46148" txt_i="31731" txt_f="31738">Sitohy </offsets><italic><offsets xml_i="46156" xml_f="46161" txt_i="31738" txt_f="31743">et al</offsets></italic><offsets xml_i="46170" xml_f="46176" txt_i="31743" txt_f="31749">, 2011</offsets></xref><offsets xml_i="46183" xml_f="46228" txt_i="31749" txt_f="31794">), which may show resistance to bevacizumab (</offsets><xref ref-type="bibr" rid="bib27"><offsets xml_i="46262" xml_f="46271" txt_i="31794" txt_f="31803">Helfrich </offsets><italic><offsets xml_i="46279" xml_f="46284" txt_i="31803" txt_f="31808">et al</offsets></italic><offsets xml_i="46293" xml_f="46299" txt_i="31808" txt_f="31814">, 2010</offsets></xref><offsets xml_i="46306" xml_f="46308" txt_i="31814" txt_f="31816">; </offsets><xref ref-type="bibr" rid="bib56"><offsets xml_i="46342" xml_f="46349" txt_i="31816" txt_f="31823">Sitohy </offsets><italic><offsets xml_i="46357" xml_f="46362" txt_i="31823" txt_f="31828">et al</offsets></italic><offsets xml_i="46371" xml_f="46377" txt_i="31828" txt_f="31834">, 2011</offsets></xref><offsets xml_i="46384" xml_f="46386" txt_i="31834" txt_f="31836">; </offsets><xref ref-type="bibr" rid="bib65"><offsets xml_i="46420" xml_f="46431" txt_i="31836" txt_f="31847">Weisshardt </offsets><italic><offsets xml_i="46439" xml_f="46444" txt_i="31847" txt_f="31852">et al</offsets></italic><offsets xml_i="46453" xml_f="46459" txt_i="31852" txt_f="31858">, 2012</offsets></xref><offsets xml_i="46466" xml_f="46706" txt_i="31858" txt_f="32098">) and might support tumour growth. Correspondingly, more hypoxia detected in our responding patients is consistent with a less-functional vasculature and might enhance the cell kill caused by chemotherapy through hypoxia-induced apoptosis (</offsets><xref ref-type="bibr" rid="bib53"><offsets xml_i="46740" xml_f="46753" txt_i="32098" txt_f="32111">Selvakumaran </offsets><italic><offsets xml_i="46761" xml_f="46766" txt_i="32111" txt_f="32116">et al</offsets></italic><offsets xml_i="46775" xml_f="46781" txt_i="32116" txt_f="32122">, 2008</offsets></xref><offsets xml_i="46788" xml_f="46937" txt_i="32122" txt_f="32271">). Higher PDGF-BB levels in the non-responding patients are also rational as they provide mitogenic signals for pericyte recruitment and maturation (</offsets><xref ref-type="bibr" rid="bib43"><offsets xml_i="46971" xml_f="46979" txt_i="32271" txt_f="32279">Lindahl </offsets><italic><offsets xml_i="46987" xml_f="46992" txt_i="32279" txt_f="32284">et al</offsets></italic><offsets xml_i="47001" xml_f="47007" txt_i="32284" txt_f="32290">, 1997</offsets></xref><offsets xml_i="47014" xml_f="47016" txt_i="32290" txt_f="32292">; </offsets><xref ref-type="bibr" rid="bib2"><offsets xml_i="47049" xml_f="47059" txt_i="32292" txt_f="32302">Abramsson </offsets><italic><offsets xml_i="47067" xml_f="47072" txt_i="32302" txt_f="32307">et al</offsets></italic><offsets xml_i="47081" xml_f="47087" txt_i="32307" txt_f="32313">, 2003</offsets></xref><offsets xml_i="47094" xml_f="47230" txt_i="32313" txt_f="32449">), and were reported to be detected in blood of progressing patients and around vessels that developed resistance to anti-VEGF therapy (</offsets><xref ref-type="bibr" rid="bib31"><offsets xml_i="47264" xml_f="47270" txt_i="32449" txt_f="32455">Huang </offsets><italic><offsets xml_i="47278" xml_f="47283" txt_i="32455" txt_f="32460">et al</offsets></italic><offsets xml_i="47292" xml_f="47298" txt_i="32460" txt_f="32466">, 2004</offsets></xref><offsets xml_i="47305" xml_f="47307" txt_i="32466" txt_f="32468">; </offsets><xref ref-type="bibr" rid="bib38"><offsets xml_i="47341" xml_f="47348" txt_i="32468" txt_f="32475">Kopetz </offsets><italic><offsets xml_i="47356" xml_f="47361" txt_i="32475" txt_f="32480">et al</offsets></italic><offsets xml_i="47370" xml_f="47376" txt_i="32480" txt_f="32486">, 2010</offsets></xref><offsets xml_i="47383" xml_f="47385" txt_i="32486" txt_f="32488">).</offsets></p><p><offsets xml_i="47392" xml_f="47694" txt_i="32489" txt_f="32791">This hypothesis, by which pericytes protect endothelial cells from anti-angiogenic therapy, promotes the combination of VEGF and PDGF inhibitors. Blocking the survival factor VEGF together with blockage of pericyte recruitment and maturation could prevent endothelial survival directly and indirectly (</offsets><xref ref-type="bibr" rid="bib54"><offsets xml_i="47728" xml_f="47736" txt_i="32791" txt_f="32799">Shaheen </offsets><italic><offsets xml_i="47744" xml_f="47749" txt_i="32799" txt_f="32804">et al</offsets></italic><offsets xml_i="47758" xml_f="47764" txt_i="32804" txt_f="32810">, 2001</offsets></xref><offsets xml_i="47771" xml_f="47773" txt_i="32810" txt_f="32812">; </offsets><xref ref-type="bibr" rid="bib7"><offsets xml_i="47806" xml_f="47832" txt_i="32812" txt_f="32838">Bergers and Benjamin, 2003</offsets></xref><offsets xml_i="47839" xml_f="47841" txt_i="32838" txt_f="32840">; </offsets><xref ref-type="bibr" rid="bib14"><offsets xml_i="47875" xml_f="47881" txt_i="32840" txt_f="32846">Erber </offsets><italic><offsets xml_i="47889" xml_f="47894" txt_i="32846" txt_f="32851">et al</offsets></italic><offsets xml_i="47903" xml_f="47909" txt_i="32851" txt_f="32857">, 2004</offsets></xref><offsets xml_i="47916" xml_f="47918" txt_i="32857" txt_f="32859">; </offsets><xref ref-type="bibr" rid="bib27"><offsets xml_i="47952" xml_f="47961" txt_i="32859" txt_f="32868">Helfrich </offsets><italic><offsets xml_i="47969" xml_f="47974" txt_i="32868" txt_f="32873">et al</offsets></italic><offsets xml_i="47983" xml_f="47989" txt_i="32873" txt_f="32879">, 2010</offsets></xref><offsets xml_i="47996" xml_f="47998" txt_i="32879" txt_f="32881">; </offsets><xref ref-type="bibr" rid="bib18"><offsets xml_i="48032" xml_f="48039" txt_i="32881" txt_f="32888">Franco </offsets><italic><offsets xml_i="48047" xml_f="48052" txt_i="32888" txt_f="32893">et al</offsets></italic><offsets xml_i="48061" xml_f="48067" txt_i="32893" txt_f="32899">, 2011</offsets></xref><offsets xml_i="48074" xml_f="48076" txt_i="32899" txt_f="32901">).</offsets></p><p><offsets xml_i="48083" xml_f="49593" txt_i="32902" txt_f="34412">The current study should be considered as a pilot study looking for hypothesis-generating hints with several limitations. The trial did not allow us to compare results between the bevacizumab-containing regimen and CRT alone, as no arm was included without bevacizumab. Moreover, many treatments are involved in producing the observed phenotype of response, masking possible interactions and confounders. Therefore, it is impossible to speculate on a prognostic or predictive effect of the biomarkers studied, and it is not clear whether the correlations with response we observed are driven by bevacizumab, by the chemotherapy, by the radiotherapy or a combination of those treatments. One cannot exclude the possibility that the hypothesis we put forward may also be the result of mechanisms next to bevacizumab activity in this setting. Owing to a small sample size, we have to be aware of limited statistical power when interpreting our data. It should be noted that several markers identified in our study as potential biomarkers show a considerable overlap between responders and non-responders, limiting their clinical applicability. It is indeed unlikely that a single biomarker will allow differentiating between responders and non-responders. However, before any of these markers can be considered a biomarker, either on its own or in a panel of different markers, these markers should be prospectively validated in independent randomised cohorts to fully assess their prognostic or predictive value.</offsets></p></sec></sec><sec sec-type="conclusions"><title><offsets xml_i="49644" xml_f="49654" txt_i="34415" txt_f="34425">Conclusion</offsets></title><p><offsets xml_i="49665" xml_f="50120" txt_i="34426" txt_f="34881">In summary, we could not support the ‘normalization hypothesis' that states that bevacizumab results in more mature blood vessels and less hypoxia. Analysis of the microarray data showed an intrinsic angiogenic phenotype displayed in tumours from patients with a pCR. Moreover, angiogenic pathways are influenced by bevacizumab only in those tumours in contrast to non-responding tumours. Our exploratory data point towards a possible prognostic role for </offsets><italic><offsets xml_i="50128" xml_f="50133" txt_i="34881" txt_f="34886">PDGFA</offsets></italic><offsets xml_i="50142" xml_f="50603" txt_i="34886" txt_f="35347">, PDGF-BB, CA-IX and pericyte-covered blood vessels. Our findings suggest a role for pericyte recruitment and vessel maturation for the susceptibility of the tumour vasculature to bevacizumab treatment. Further exploration of our mechanistic hypothesis and validation of the candidate markers is demanded in large, well-powered randomised studies in order to contribute to a more rational therapeutic approach of anti-angiogenic agents in combinations with CRT.</offsets></p></sec></body><back><ack><p>KH and AD are supported by a fundamental clinical mandate and a post-doctoral research mandate of the FWO, respectively. JD is supported by the Flemish League against Cancer (VLK). This work was supported by Varian, and conducted with support from Roche, Sanofi Aventis and ‘Vlaamse Liga tegen Kanker'.</p></ack><fn-group><fn><p><xref ref-type="supplementary-material" rid="sup1">Supplementary Information</xref> accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)</p></fn><fn><p>This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.</p></fn></fn-group><notes><p>The authors declare no conflict of interest.</p></notes><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abajo</surname><given-names>A</given-names></name><name><surname>Boni</surname><given-names>V</given-names></name><name><surname>Lopez</surname><given-names>I</given-names></name><name><surname>Gonzalez-Huarriz</surname><given-names>M</given-names></name><name><surname>Bitarte</surname><given-names>N</given-names></name><name><surname>Rodriguez</surname><given-names>J</given-names></name><name><surname>Zarate</surname><given-names>R</given-names></name><name><surname>Bandres</surname><given-names>E</given-names></name><name><surname>Garcia-Foncillas</surname><given-names>J</given-names></name></person-group><year>2012</year><article-title>Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients</article-title><source>Br J Cancer</source><volume>107</volume><supplement>(2</supplement><fpage>287</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">22699823</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abramsson</surname><given-names>A</given-names></name><name><surname>Lindblom</surname><given-names>P</given-names></name><name><surname>Betsholtz</surname><given-names>C</given-names></name></person-group><year>2003</year><article-title>Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors</article-title><source>J Clin Invest</source><volume>112</volume><supplement>(8</supplement><fpage>1142</fpage><lpage>1151</lpage><pub-id pub-id-type="pmid">14561699</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aklilu</surname><given-names>M</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name></person-group><year>2011</year><article-title>The current landscape of locally advanced rectal cancer</article-title><source>Nat Rev Clin Oncol</source><volume>8</volume><supplement>(11</supplement><fpage>649</fpage><lpage>659</lpage><pub-id pub-id-type="pmid">21826084</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aschele</surname><given-names>C</given-names></name><name><surname>Cionini</surname><given-names>L</given-names></name><name><surname>Lonardi</surname><given-names>S</given-names></name><name><surname>Pinto</surname><given-names>C</given-names></name><name><surname>Cordio</surname><given-names>S</given-names></name><name><surname>Rosati</surname><given-names>G</given-names></name><name><surname>Artale</surname><given-names>S</given-names></name><name><surname>Tagliagambe</surname><given-names>A</given-names></name><name><surname>Ambrosini</surname><given-names>G</given-names></name><name><surname>Rosetti</surname><given-names>P</given-names></name><name><surname>Bonetti</surname><given-names>A</given-names></name><name><surname>Negru</surname><given-names>ME</given-names></name><name><surname>Tronconi</surname><given-names>MC</given-names></name><name><surname>Luppi</surname><given-names>G</given-names></name><name><surname>Silvano</surname><given-names>G</given-names></name><name><surname>Corsi</surname><given-names>DC</given-names></name><name><surname>Bochicchio</surname><given-names>AM</given-names></name><name><surname>Chiaulon</surname><given-names>G</given-names></name><name><surname>Gallo</surname><given-names>M</given-names></name><name><surname>Boni</surname><given-names>L</given-names></name></person-group><year>2011</year><article-title>Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial</article-title><source>J Clin Oncol</source><volume>29</volume><supplement>(20</supplement><fpage>2773</fpage><lpage>2780</lpage><pub-id pub-id-type="pmid">21606427</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamin</surname><given-names>LE</given-names></name><name><surname>Hemo</surname><given-names>I</given-names></name><name><surname>Keshet</surname><given-names>E</given-names></name></person-group><year>1998</year><article-title>A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF</article-title><source>Development</source><volume>125</volume><supplement>(9</supplement><fpage>1591</fpage><lpage>1598</lpage><pub-id pub-id-type="pmid">9521897</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group><year>1995</year><article-title>Controlling the false discovery rate: a practival and powerful approach to multiple testing</article-title><source>J R Statist Soc Ser B</source><volume>57</volume><fpage>289</fpage><lpage>300</lpage></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergers</surname><given-names>G</given-names></name><name><surname>Benjamin</surname><given-names>LE</given-names></name></person-group><year>2003</year><article-title>Tumorigenesis and the angiogenic switch</article-title><source>Nat Rev Cancer</source><volume>3</volume><supplement>(6</supplement><fpage>401</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">12778130</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brauer</surname><given-names>MJ</given-names></name><name><surname>Zhuang</surname><given-names>G</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Kaminker</surname><given-names>JS</given-names></name><name><surname>Jurinka</surname><given-names>SS</given-names></name><name><surname>Kolumam</surname><given-names>G</given-names></name><name><surname>Chung</surname><given-names>AS</given-names></name><name><surname>Jubb</surname><given-names>A</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><name><surname>Ozawa</surname><given-names>T</given-names></name><name><surname>James</surname><given-names>CD</given-names></name><name><surname>Phillips</surname><given-names>H</given-names></name><name><surname>Haley</surname><given-names>B</given-names></name><name><surname>Tam</surname><given-names>RN</given-names></name><name><surname>Clermont</surname><given-names>AC</given-names></name><name><surname>Cheng</surname><given-names>JH</given-names></name><name><surname>Yang</surname><given-names>SX</given-names></name><name><surname>Swain</surname><given-names>SM</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Scherer</surname><given-names>SJ</given-names></name><name><surname>Koeppen</surname><given-names>H</given-names></name><name><surname>Yeh</surname><given-names>RF</given-names></name><name><surname>Yue</surname><given-names>P</given-names></name><name><surname>Stephan</surname><given-names>JP</given-names></name><name><surname>Hegde</surname><given-names>P</given-names></name><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Bais</surname><given-names>C</given-names></name></person-group><year>2013</year><article-title>Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies</article-title><source>Clin Cancer Res</source><volume>19</volume><supplement>(13</supplement><fpage>3681</fpage><lpage>3692</lpage><pub-id pub-id-type="pmid">23685835</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brostjan</surname><given-names>C</given-names></name><name><surname>Gebhardt</surname><given-names>K</given-names></name><name><surname>Gruenberger</surname><given-names>B</given-names></name><name><surname>Steinrueck</surname><given-names>V</given-names></name><name><surname>Zommer</surname><given-names>H</given-names></name><name><surname>Freudenthaler</surname><given-names>H</given-names></name><name><surname>Roka</surname><given-names>S</given-names></name><name><surname>Gruenberger</surname><given-names>T</given-names></name></person-group><year>2008</year><article-title>Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels</article-title><source>Clin Cancer Res</source><volume>14</volume><supplement>(7</supplement><fpage>2065</fpage><lpage>2074</lpage><pub-id pub-id-type="pmid">18381946</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crane</surname><given-names>CH</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Feig</surname><given-names>BW</given-names></name><name><surname>Das</surname><given-names>P</given-names></name><name><surname>Skibber</surname><given-names>JM</given-names></name><name><surname>Chang</surname><given-names>GJ</given-names></name><name><surname>Wolff</surname><given-names>RA</given-names></name><name><surname>Krishnan</surname><given-names>S</given-names></name><name><surname>Hamilton</surname><given-names>S</given-names></name><name><surname>Janjan</surname><given-names>NA</given-names></name><name><surname>Maru</surname><given-names>DM</given-names></name><name><surname>Ellis</surname><given-names>LM</given-names></name><name><surname>Rodriguez-Bigas</surname><given-names>MA</given-names></name></person-group><year>2010</year><article-title>Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>76</volume><supplement>(3</supplement><fpage>824</fpage><lpage>830</lpage><pub-id pub-id-type="pmid">19464823</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czito</surname><given-names>BG</given-names></name><name><surname>Bendell</surname><given-names>JC</given-names></name><name><surname>Willett</surname><given-names>CG</given-names></name><name><surname>Morse</surname><given-names>MA</given-names></name><name><surname>Blobe</surname><given-names>GC</given-names></name><name><surname>Tyler</surname><given-names>DS</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Ludwig</surname><given-names>KA</given-names></name><name><surname>Mantyh</surname><given-names>CR</given-names></name><name><surname>Ashton</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Hurwitz</surname><given-names>HI</given-names></name></person-group><year>2007</year><article-title>Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>68</volume><supplement>(2</supplement><fpage>472</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">17498568</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darland</surname><given-names>DC</given-names></name><name><surname>Massingham</surname><given-names>LJ</given-names></name><name><surname>Smith</surname><given-names>SR</given-names></name><name><surname>Piek</surname><given-names>E</given-names></name><name><surname>Saint-Geniez</surname><given-names>M</given-names></name><name><surname>D'Amore</surname><given-names>PA</given-names></name></person-group><year>2003</year><article-title>Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival</article-title><source>Dev Biol</source><volume>264</volume><supplement>(1</supplement><fpage>275</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">14623248</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellas</surname><given-names>K</given-names></name><name><surname>Hohler</surname><given-names>T</given-names></name><name><surname>Reese</surname><given-names>T</given-names></name><name><surname>Wurschmidt</surname><given-names>F</given-names></name><name><surname>Engel</surname><given-names>E</given-names></name><name><surname>Rodel</surname><given-names>C</given-names></name><name><surname>Wagner</surname><given-names>W</given-names></name><name><surname>Richter</surname><given-names>M</given-names></name><name><surname>Arnold</surname><given-names>D</given-names></name><name><surname>Dunst</surname><given-names>J</given-names></name></person-group><year>2013</year><article-title>Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer</article-title><source>Radiat Oncol</source><volume>8</volume><supplement>(1</supplement><fpage>90</fpage><pub-id pub-id-type="pmid">23587311</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erber</surname><given-names>R</given-names></name><name><surname>Thurnher</surname><given-names>A</given-names></name><name><surname>Katsen</surname><given-names>AD</given-names></name><name><surname>Groth</surname><given-names>G</given-names></name><name><surname>Kerger</surname><given-names>H</given-names></name><name><surname>Hammes</surname><given-names>HP</given-names></name><name><surname>Menger</surname><given-names>MD</given-names></name><name><surname>Ullrich</surname><given-names>A</given-names></name><name><surname>Vajkoczy</surname><given-names>P</given-names></name></person-group><year>2004</year><article-title>Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms</article-title><source>FASEB J</source><volume>18</volume><supplement>(2</supplement><fpage>338</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">14657001</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evensen</surname><given-names>L</given-names></name><name><surname>Micklem</surname><given-names>DR</given-names></name><name><surname>Blois</surname><given-names>A</given-names></name><name><surname>Berge</surname><given-names>SV</given-names></name><name><surname>Aarsaether</surname><given-names>N</given-names></name><name><surname>Littlewood-Evans</surname><given-names>A</given-names></name><name><surname>Wood</surname><given-names>J</given-names></name><name><surname>Lorens</surname><given-names>JB</given-names></name></person-group><year>2009</year><article-title>Mural cell associated VEGF is required for organotypic vessel formation</article-title><source>PLoS One</source><volume>4</volume><supplement>(6</supplement><fpage>e5798</fpage><pub-id pub-id-type="pmid">19495422</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Foernzler</surname><given-names>D</given-names></name><name><surname>Delmar</surname><given-names>P</given-names></name><name><surname>Kockx</surname><given-names>M</given-names></name><name><surname>Cassidy</surname><given-names>J</given-names></name><name><surname>Saltz</surname><given-names>L</given-names></name><name><surname>Scherer</surname><given-names>S</given-names></name></person-group><year>2010</year><article-title>Tumor tissue based biomarker analysis in NO16966: a randomized phase III study of first-line bevacizumab in combination with oxaliplatin-based chemotherapy in patients with mCRC</article-title><source>ASCO GastroIntestinal Cancers Symposium</source>January 2010: abstract 374.</mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franceschini</surname><given-names>A</given-names></name><name><surname>Szklarczyk</surname><given-names>D</given-names></name><name><surname>Frankild</surname><given-names>S</given-names></name><name><surname>Kuhn</surname><given-names>M</given-names></name><name><surname>Simonovic</surname><given-names>M</given-names></name><name><surname>Roth</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Minguez</surname><given-names>P</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>von</surname><given-names>MC</given-names></name><name><surname>Jensen</surname><given-names>LJ</given-names></name></person-group><year>2013</year><article-title>STRING v9.1: protein-protein interaction networks, with increased coverage and integration</article-title><source>Nucleic Acids Res</source><volume>41</volume><supplement>(Database issue</supplement><fpage>D808</fpage><lpage>D815</lpage><pub-id pub-id-type="pmid">23203871</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franco</surname><given-names>M</given-names></name><name><surname>Roswall</surname><given-names>P</given-names></name><name><surname>Cortez</surname><given-names>E</given-names></name><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Pietras</surname><given-names>K</given-names></name></person-group><year>2011</year><article-title>Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression</article-title><source>Blood</source><volume>118</volume><supplement>(10</supplement><fpage>2906</fpage><lpage>2917</lpage><pub-id pub-id-type="pmid">21778339</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>RE</given-names></name><name><surname>Saclarides</surname><given-names>TJ</given-names></name><name><surname>Leurgans</surname><given-names>S</given-names></name><name><surname>Speziale</surname><given-names>NJ</given-names></name><name><surname>Drab</surname><given-names>EA</given-names></name><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group><year>1995</year><article-title>Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer</article-title><source>Ann Surg</source><volume>222</volume><supplement>(6</supplement><fpage>695</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">8526575</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galizia</surname><given-names>G</given-names></name><name><surname>Lieto</surname><given-names>E</given-names></name><name><surname>Ferraraccio</surname><given-names>F</given-names></name><name><surname>Orditura</surname><given-names>M</given-names></name><name><surname>De</surname><given-names>VF</given-names></name><name><surname>Castellano</surname><given-names>P</given-names></name><name><surname>Imperatore</surname><given-names>V</given-names></name><name><surname>Romano</surname><given-names>C</given-names></name><name><surname>Ciardiello</surname><given-names>F</given-names></name><name><surname>Agostini</surname><given-names>B</given-names></name><name><surname>Pignatelli</surname><given-names>C</given-names></name></person-group><year>2004</year><article-title>Determination of molecular marker expression can predict clinical outcome in colon carcinomas</article-title><source>Clin Cancer Res</source><volume>10</volume><supplement>(10</supplement><fpage>3490</fpage><lpage>3499</lpage><pub-id pub-id-type="pmid">15161706</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasparini</surname><given-names>G</given-names></name><name><surname>Torino</surname><given-names>F</given-names></name><name><surname>Ueno</surname><given-names>T</given-names></name><name><surname>Cascinu</surname><given-names>S</given-names></name><name><surname>Troiani</surname><given-names>T</given-names></name><name><surname>Ballestrero</surname><given-names>A</given-names></name><name><surname>Berardi</surname><given-names>R</given-names></name><name><surname>Shishido</surname><given-names>J</given-names></name><name><surname>Yoshizawa</surname><given-names>A</given-names></name><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Nagayama</surname><given-names>S</given-names></name><name><surname>Morosini</surname><given-names>P</given-names></name><name><surname>Toi</surname><given-names>M</given-names></name></person-group><year>2012</year><article-title>A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer</article-title><source>Angiogenesis</source><volume>15</volume><supplement>(1</supplement><fpage>141</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">22212406</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaur</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Ann</surname><given-names>V</given-names></name><name><surname>Lin</surname><given-names>WC</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>VH</given-names></name><name><surname>Hsu</surname><given-names>NY</given-names></name><name><surname>Shia</surname><given-names>HS</given-names></name><name><surname>Yen</surname><given-names>Y</given-names></name></person-group><year>2014</year><article-title>Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status</article-title><source>Mol Cancer</source><volume>13</volume><fpage>21</fpage><pub-id pub-id-type="pmid">24495750</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gentleman</surname><given-names>RC</given-names></name><name><surname>Carey</surname><given-names>VJ</given-names></name><name><surname>Bates</surname><given-names>DM</given-names></name><name><surname>Bolstad</surname><given-names>B</given-names></name><name><surname>Dettling</surname><given-names>M</given-names></name><name><surname>Dudoit</surname><given-names>S</given-names></name><name><surname>Ellis</surname><given-names>B</given-names></name><name><surname>Gautier</surname><given-names>L</given-names></name><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Gentry</surname><given-names>J</given-names></name><name><surname>Hornik</surname><given-names>K</given-names></name><name><surname>Hothorn</surname><given-names>T</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Iacus</surname><given-names>S</given-names></name><name><surname>Irizarry</surname><given-names>R</given-names></name><name><surname>Leisch</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Maechler</surname><given-names>M</given-names></name><name><surname>Rossini</surname><given-names>AJ</given-names></name><name><surname>Sawitzki</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Smyth</surname><given-names>G</given-names></name><name><surname>Tierney</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>JY</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year>2004</year><article-title>Bioconductor: open software development for computational biology and bioinformatics</article-title><source>Genome Biol</source><volume>5</volume><supplement>(10</supplement><fpage>R80</fpage><pub-id pub-id-type="pmid">15461798</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerard</surname><given-names>JP</given-names></name><name><surname>Azria</surname><given-names>D</given-names></name><name><surname>Gourgou-Bourgade</surname><given-names>S</given-names></name><name><surname>Martel-Laffay</surname><given-names>I</given-names></name><name><surname>Hennequin</surname><given-names>C</given-names></name><name><surname>Etienne</surname><given-names>PL</given-names></name><name><surname>Vendrely</surname><given-names>V</given-names></name><name><surname>Francois</surname><given-names>E</given-names></name><name><surname>de La</surname><given-names>RG</given-names></name><name><surname>Bouche</surname><given-names>O</given-names></name><name><surname>Mirabel</surname><given-names>X</given-names></name><name><surname>Denis</surname><given-names>B</given-names></name><name><surname>Mineur</surname><given-names>L</given-names></name><name><surname>Berdah</surname><given-names>JF</given-names></name><name><surname>Mahe</surname><given-names>MA</given-names></name><name><surname>Becouarn</surname><given-names>Y</given-names></name><name><surname>Dupuis</surname><given-names>O</given-names></name><name><surname>Lledo</surname><given-names>G</given-names></name><name><surname>Montoto-Grillot</surname><given-names>C</given-names></name><name><surname>Conroy</surname><given-names>T</given-names></name></person-group><year>2010</year><article-title>Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2</article-title><source>J Clin Oncol</source><volume>28</volume><supplement>(10</supplement><fpage>1638</fpage><lpage>1644</lpage><pub-id pub-id-type="pmid">20194850</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giatromanolaki</surname><given-names>A</given-names></name><name><surname>Koukourakis</surname><given-names>MI</given-names></name><name><surname>Sivridis</surname><given-names>E</given-names></name><name><surname>Gatter</surname><given-names>KC</given-names></name><name><surname>Trarbach</surname><given-names>T</given-names></name><name><surname>Folprecht</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>MM</given-names></name><name><surname>Lebwohl</surname><given-names>D</given-names></name><name><surname>Jalava</surname><given-names>T</given-names></name><name><surname>Laurent</surname><given-names>D</given-names></name><name><surname>Meinhardt</surname><given-names>G</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name></person-group><year>2012</year><article-title>Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials</article-title><source>Br J Cancer</source><volume>107</volume><supplement>(7</supplement><fpage>1044</fpage><lpage>1050</lpage><pub-id pub-id-type="pmid">22910317</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goede</surname><given-names>V</given-names></name><name><surname>Coutelle</surname><given-names>O</given-names></name><name><surname>Neuneier</surname><given-names>J</given-names></name><name><surname>Reinacher-Schick</surname><given-names>A</given-names></name><name><surname>Schnell</surname><given-names>R</given-names></name><name><surname>Koslowsky</surname><given-names>TC</given-names></name><name><surname>Weihrauch</surname><given-names>MR</given-names></name><name><surname>Cremer</surname><given-names>B</given-names></name><name><surname>Kashkar</surname><given-names>H</given-names></name><name><surname>Odenthal</surname><given-names>M</given-names></name><name><surname>Augustin</surname><given-names>HG</given-names></name><name><surname>Schmiegel</surname><given-names>W</given-names></name><name><surname>Hallek</surname><given-names>M</given-names></name><name><surname>Hacker</surname><given-names>UT</given-names></name></person-group><year>2010</year><article-title>Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy</article-title><source>Br J Cancer</source><volume>103</volume><supplement>(9</supplement><fpage>1407</fpage><lpage>1414</lpage><pub-id pub-id-type="pmid">20924372</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helfrich</surname><given-names>I</given-names></name><name><surname>Scheffrahn</surname><given-names>I</given-names></name><name><surname>Bartling</surname><given-names>S</given-names></name><name><surname>Weis</surname><given-names>J</given-names></name><name><surname>von Felbert</surname><given-names>V</given-names></name><name><surname>Middleton</surname><given-names>M</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Ergun</surname><given-names>S</given-names></name><name><surname>Augustin</surname><given-names>HG</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name></person-group><year>2010</year><article-title>Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma</article-title><source>J Exp Med</source><volume>207</volume><supplement>(3</supplement><fpage>491</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">20194633</pub-id></mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>YS</given-names></name><name><surname>Cho</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Jung</surname><given-names>KH</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Choi</surname><given-names>HS</given-names></name><name><surname>Oh</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>BC</given-names></name><name><surname>Sohn</surname><given-names>DK</given-names></name><name><surname>Kim</surname><given-names>DY</given-names></name><name><surname>Chang</surname><given-names>HJ</given-names></name></person-group><year>2009</year><article-title>Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer</article-title><source>BMC Cancer</source><volume>9</volume><fpage>246</fpage><pub-id pub-id-type="pmid">19619339</pub-id></mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Petillo</surname><given-names>D</given-names></name><name><surname>Qian</surname><given-names>CN</given-names></name><name><surname>Kahnoski</surname><given-names>R</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Furge</surname><given-names>KA</given-names></name><name><surname>Teh</surname><given-names>BT</given-names></name></person-group><year>2010</year><article-title>Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma</article-title><source>Cancer Res</source><volume>70</volume><supplement>(3</supplement><fpage>1063</fpage><lpage>1071</lpage><pub-id pub-id-type="pmid">20103651</pub-id></mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>dW</given-names></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Lempicki</surname><given-names>RA</given-names></name></person-group><year>2009</year><article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title><source>Nat Protoc</source><volume>4</volume><supplement>(1</supplement><fpage>44</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">19131956</pub-id></mixed-citation></ref><ref id="bib31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Soffer</surname><given-names>SZ</given-names></name><name><surname>Kim</surname><given-names>ES</given-names></name><name><surname>McCrudden</surname><given-names>KW</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>New</surname><given-names>T</given-names></name><name><surname>Manley</surname><given-names>CA</given-names></name><name><surname>Middlesworth</surname><given-names>W</given-names></name><name><surname>O'Toole</surname><given-names>K</given-names></name><name><surname>Yamashiro</surname><given-names>DJ</given-names></name><name><surname>Kandel</surname><given-names>JJ</given-names></name></person-group><year>2004</year><article-title>Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis</article-title><source>Mol Cancer Res</source><volume>2</volume><supplement>(1</supplement><fpage>36</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">14757844</pub-id></mixed-citation></ref><ref id="bib32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inanc</surname><given-names>M</given-names></name><name><surname>Er</surname><given-names>O</given-names></name><name><surname>Karaca</surname><given-names>H</given-names></name><name><surname>Berk</surname><given-names>V</given-names></name><name><surname>Ozkan</surname><given-names>M</given-names></name><name><surname>Saraymen</surname><given-names>R</given-names></name><name><surname>Elmali</surname><given-names>F</given-names></name></person-group><year>2012</year><article-title>Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer</article-title><source>Med Oncol</source><volume>29</volume><supplement>(5</supplement><fpage>3119</fpage><lpage>3124</lpage><pub-id pub-id-type="pmid">22580817</pub-id></mixed-citation></ref><ref id="bib33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><year>2001</year><article-title>Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy</article-title><source>Nat Med</source><volume>7</volume><supplement>(9</supplement><fpage>987</fpage><lpage>989</lpage><pub-id pub-id-type="pmid">11533692</pub-id></mixed-citation></ref><ref id="bib34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><year>2005</year><article-title>Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy</article-title><source>Science</source><volume>307</volume><supplement>(5706</supplement><fpage>58</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15637262</pub-id></mixed-citation></ref><ref id="bib35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jubb</surname><given-names>AM</given-names></name><name><surname>Hurwitz</surname><given-names>HI</given-names></name><name><surname>Bai</surname><given-names>W</given-names></name><name><surname>Holmgren</surname><given-names>EB</given-names></name><name><surname>Tobin</surname><given-names>P</given-names></name><name><surname>Guerrero</surname><given-names>AS</given-names></name><name><surname>Kabbinavar</surname><given-names>F</given-names></name><name><surname>Holden</surname><given-names>SN</given-names></name><name><surname>Novotny</surname><given-names>WF</given-names></name><name><surname>Frantz</surname><given-names>GD</given-names></name><name><surname>Hillan</surname><given-names>KJ</given-names></name><name><surname>Koeppen</surname><given-names>H</given-names></name></person-group><year>2006</year><article-title>Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer</article-title><source>J Clin Oncol</source><volume>24</volume><supplement>(2</supplement><fpage>217</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">16365183</pub-id></mixed-citation></ref><ref id="bib36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennecke</surname><given-names>H</given-names></name><name><surname>Berry</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Tankel</surname><given-names>K</given-names></name><name><surname>Easaw</surname><given-names>J</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Post</surname><given-names>J</given-names></name><name><surname>Hay</surname><given-names>J</given-names></name></person-group><year>2012</year><article-title>Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial</article-title><source>Eur J Cancer</source><volume>48</volume><supplement>(1</supplement><fpage>37</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">21664123</pub-id></mixed-citation></ref><ref id="bib37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khatri</surname><given-names>P</given-names></name><name><surname>Draghici</surname><given-names>S</given-names></name></person-group><year>2005</year><article-title>Ontological analysis of gene expression data: current tools, limitations, and open problems</article-title><source>Bioinformatics</source><volume>21</volume><supplement>(18</supplement><fpage>3587</fpage><lpage>3595</lpage><pub-id pub-id-type="pmid">15994189</pub-id></mixed-citation></ref><ref id="bib38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopetz</surname><given-names>S</given-names></name><name><surname>Hoff</surname><given-names>PM</given-names></name><name><surname>Morris</surname><given-names>JS</given-names></name><name><surname>Wolff</surname><given-names>RA</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Glover</surname><given-names>KY</given-names></name><name><surname>Adinin</surname><given-names>R</given-names></name><name><surname>Overman</surname><given-names>MJ</given-names></name><name><surname>Valero</surname><given-names>V</given-names></name><name><surname>Wen</surname><given-names>S</given-names></name><name><surname>Lieu</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>S</given-names></name><name><surname>Tran</surname><given-names>HT</given-names></name><name><surname>Ellis</surname><given-names>LM</given-names></name><name><surname>Abbruzzese</surname><given-names>JL</given-names></name><name><surname>Heymach</surname><given-names>JV</given-names></name></person-group><year>2010</year><article-title>Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance</article-title><source>J Clin Oncol</source><volume>28</volume><supplement>(3</supplement><fpage>453</fpage><lpage>459</lpage><pub-id pub-id-type="pmid">20008624</pub-id></mixed-citation></ref><ref id="bib39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koukourakis</surname><given-names>MI</given-names></name><name><surname>Giatromanolaki</surname><given-names>A</given-names></name><name><surname>Sheldon</surname><given-names>H</given-names></name><name><surname>Buffa</surname><given-names>FM</given-names></name><name><surname>Kouklakis</surname><given-names>G</given-names></name><name><surname>Ragoussis</surname><given-names>I</given-names></name><name><surname>Sivridis</surname><given-names>E</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name></person-group><year>2009</year><article-title>Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab</article-title><source>Clin Cancer Res</source><volume>15</volume><supplement>(22</supplement><fpage>7069</fpage><lpage>7076</lpage><pub-id pub-id-type="pmid">19887481</pub-id></mixed-citation></ref><ref id="bib40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koukourakis</surname><given-names>MI</given-names></name><name><surname>Giatromanolaki</surname><given-names>A</given-names></name><name><surname>Tsoutsou</surname><given-names>P</given-names></name><name><surname>Lyratzopoulos</surname><given-names>N</given-names></name><name><surname>Pitiakoudis</surname><given-names>M</given-names></name><name><surname>Kouklakis</surname><given-names>G</given-names></name><name><surname>Chloropoulou</surname><given-names>PA</given-names></name><name><surname>Manolas</surname><given-names>K</given-names></name><name><surname>Sivridis</surname><given-names>E</given-names></name></person-group><year>2011</year><article-title>Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a Phase II study</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>80</volume><supplement>(2</supplement><fpage>492</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">20584585</pub-id></mixed-citation></ref><ref id="bib41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambrechts</surname><given-names>D</given-names></name><name><surname>Lenz</surname><given-names>HJ</given-names></name><name><surname>de Haas</surname><given-names>S</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name><name><surname>Scherer</surname><given-names>SJ</given-names></name></person-group><year>2013</year><article-title>Markers of response for the antiangiogenic agent bevacizumab</article-title><source>J Clin Oncol</source><volume>31</volume><supplement>(9</supplement><fpage>1219</fpage><lpage>1230</lpage><pub-id pub-id-type="pmid">23401453</pub-id></mixed-citation></ref><ref id="bib42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landry</surname><given-names>JC</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Cohen</surname><given-names>SJ</given-names></name><name><surname>Staley</surname><given-names>CA</given-names><suffix>III</suffix></name><name><surname>Whittington</surname><given-names>R</given-names></name><name><surname>Sigurdson</surname><given-names>ER</given-names></name><name><surname>Nimeiri</surname><given-names>H</given-names></name><name><surname>Verma</surname><given-names>U</given-names></name><name><surname>Prabhu</surname><given-names>RS</given-names></name><name><surname>Benson</surname><given-names>AB</given-names></name></person-group><year>2013</year><article-title>Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204</article-title><source>Cancer</source><volume>119</volume><supplement>(8</supplement><fpage>1521</fpage><lpage>1527</lpage><pub-id pub-id-type="pmid">23288663</pub-id></mixed-citation></ref><ref id="bib43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindahl</surname><given-names>P</given-names></name><name><surname>Johansson</surname><given-names>BR</given-names></name><name><surname>Leveen</surname><given-names>P</given-names></name><name><surname>Betsholtz</surname><given-names>C</given-names></name></person-group><year>1997</year><article-title>Pericyte loss and microaneurysm formation in PDGF-B-deficient mice</article-title><source>Science</source><volume>277</volume><supplement>(5323</supplement><fpage>242</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">9211853</pub-id></mixed-citation></ref><ref id="bib44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Starr</surname><given-names>MD</given-names></name><name><surname>Bulusu</surname><given-names>A</given-names></name><name><surname>Pang</surname><given-names>H</given-names></name><name><surname>Wong</surname><given-names>NS</given-names></name><name><surname>Honeycutt</surname><given-names>W</given-names></name><name><surname>Amara</surname><given-names>A</given-names></name><name><surname>Hurwitz</surname><given-names>HI</given-names></name><name><surname>Nixon</surname><given-names>AB</given-names></name></person-group><year>2013</year><article-title>Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab</article-title><source>Cancer Med</source><volume>2</volume><supplement>(2</supplement><fpage>234</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">23634291</pub-id></mixed-citation></ref><ref id="bib45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loupakis</surname><given-names>F</given-names></name><name><surname>Cremolini</surname><given-names>C</given-names></name><name><surname>Fioravanti</surname><given-names>A</given-names></name><name><surname>Orlandi</surname><given-names>P</given-names></name><name><surname>Salvatore</surname><given-names>L</given-names></name><name><surname>Masi</surname><given-names>G</given-names></name><name><surname>Di</surname><given-names>DT</given-names></name><name><surname>Canu</surname><given-names>B</given-names></name><name><surname>Schirripa</surname><given-names>M</given-names></name><name><surname>Frumento</surname><given-names>P</given-names></name><name><surname>Di</surname><given-names>PA</given-names></name><name><surname>Danesi</surname><given-names>R</given-names></name><name><surname>Falcone</surname><given-names>A</given-names></name><name><surname>Bocci</surname><given-names>G</given-names></name></person-group><year>2011</year><article-title>Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer</article-title><source>Br J Cancer</source><volume>104</volume><supplement>(8</supplement><fpage>1262</fpage><lpage>1269</lpage><pub-id pub-id-type="pmid">21407216</pub-id></mixed-citation></ref><ref id="bib46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loupakis</surname><given-names>F</given-names></name><name><surname>Falcone</surname><given-names>A</given-names></name><name><surname>Masi</surname><given-names>G</given-names></name><name><surname>Fioravanti</surname><given-names>A</given-names></name><name><surname>Kerbel</surname><given-names>RS</given-names></name><name><surname>Del</surname><given-names>TM</given-names></name><name><surname>Bocci</surname><given-names>G</given-names></name></person-group><year>2007</year><article-title>Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity</article-title><source>J Clin Oncol</source><volume>25</volume><supplement>(13</supplement><fpage>1816</fpage><lpage>1818</lpage><pub-id pub-id-type="pmid">17470880</pub-id></mixed-citation></ref><ref id="bib47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loven</surname><given-names>D</given-names></name><name><surname>Be'ery</surname><given-names>E</given-names></name><name><surname>Yerushalmi</surname><given-names>R</given-names></name><name><surname>Koren</surname><given-names>C</given-names></name><name><surname>Sulkes</surname><given-names>A</given-names></name><name><surname>Lavi</surname><given-names>I</given-names></name><name><surname>Shaked</surname><given-names>Y</given-names></name><name><surname>Fenig</surname><given-names>E</given-names></name></person-group><year>2008</year><article-title>Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients</article-title><source>Acta Oncol</source><volume>47</volume><supplement>(1</supplement><fpage>104</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">17851858</pub-id></mixed-citation></ref><ref id="bib48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogue</surname><given-names>M</given-names></name><name><surname>Salud</surname><given-names>A</given-names></name><name><surname>Vicente</surname><given-names>P</given-names></name><name><surname>Arrivi</surname><given-names>A</given-names></name><name><surname>Roca</surname><given-names>JM</given-names></name><name><surname>Losa</surname><given-names>F</given-names></name><name><surname>Ponce</surname><given-names>J</given-names></name><name><surname>Safont</surname><given-names>MJ</given-names></name><name><surname>Guasch</surname><given-names>I</given-names></name><name><surname>Moreno</surname><given-names>I</given-names></name><name><surname>Ruiz</surname><given-names>A</given-names></name><name><surname>Pericay</surname><given-names>C</given-names></name></person-group><year>2011</year><article-title>Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study</article-title><source>Oncologist</source><volume>16</volume><supplement>(5</supplement><fpage>614</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">21467148</pub-id></mixed-citation></ref><ref id="bib49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Resch</surname><given-names>G</given-names></name><name><surname>De</surname><given-names>VA</given-names></name><name><surname>Ofner</surname><given-names>D</given-names></name><name><surname>Eisterer</surname><given-names>W</given-names></name><name><surname>Rabl</surname><given-names>H</given-names></name><name><surname>Jagoditsch</surname><given-names>M</given-names></name><name><surname>Gnant</surname><given-names>M</given-names></name><name><surname>Thaler</surname><given-names>J</given-names></name></person-group><year>2012</year><article-title>Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer - a two stage phase II clinical trial</article-title><source>Radiother Oncol</source><volume>102</volume><supplement>(1</supplement><fpage>10</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">21741716</pub-id></mixed-citation></ref><ref id="bib50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodel</surname><given-names>C</given-names></name><name><surname>Liersch</surname><given-names>T</given-names></name><name><surname>Becker</surname><given-names>H</given-names></name><name><surname>Fietkau</surname><given-names>R</given-names></name><name><surname>Hohenberger</surname><given-names>W</given-names></name><name><surname>Hothorn</surname><given-names>T</given-names></name><name><surname>Graeven</surname><given-names>U</given-names></name><name><surname>Arnold</surname><given-names>D</given-names></name><name><surname>Lang-Welzenbach</surname><given-names>M</given-names></name><name><surname>Raab</surname><given-names>HR</given-names></name><name><surname>Sulberg</surname><given-names>H</given-names></name><name><surname>Wittekind</surname><given-names>C</given-names></name><name><surname>Potapov</surname><given-names>S</given-names></name><name><surname>Staib</surname><given-names>L</given-names></name><name><surname>Hess</surname><given-names>C</given-names></name><name><surname>Weigang-Kohler</surname><given-names>K</given-names></name><name><surname>Grabenbauer</surname><given-names>GG</given-names></name><name><surname>Hoffmanns</surname><given-names>H</given-names></name><name><surname>Lindemann</surname><given-names>F</given-names></name><name><surname>Schlenska-Lange</surname><given-names>A</given-names></name><name><surname>Folprecht</surname><given-names>G</given-names></name><name><surname>Sauer</surname><given-names>R</given-names></name></person-group><year>2012</year><article-title>Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial</article-title><source>Lancet Oncol</source><volume>13</volume><supplement>(7</supplement><fpage>679</fpage><lpage>687</lpage><pub-id pub-id-type="pmid">22627104</pub-id></mixed-citation></ref><ref id="bib51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roh</surname><given-names>MS</given-names></name><name><surname>Yothers</surname><given-names>GA</given-names></name><name><surname>O'Connell</surname><given-names>MJ</given-names></name><name><surname>Beart</surname><given-names>W</given-names></name><name><surname>Pitot</surname><given-names>HC</given-names></name><name><surname>Shields</surname><given-names>AF</given-names></name><name><surname>Parda</surname><given-names>DS</given-names></name><name><surname>Sharif</surname><given-names>S</given-names></name><name><surname>Allegra</surname><given-names>CJ</given-names></name><name><surname>Petrelli</surname><given-names>NJ</given-names></name><name><surname>Landry</surname><given-names>JC</given-names></name><name><surname>Ryan</surname><given-names>DP</given-names></name><name><surname>Arora</surname><given-names>TL</given-names></name><name><surname>Evans</surname><given-names>TL</given-names></name><name><surname>Soori</surname><given-names>GS</given-names></name><name><surname>Chu</surname><given-names>RV</given-names></name><name><surname>Landes</surname><given-names>RV</given-names></name><name><surname>Mohiuddin</surname><given-names>M</given-names></name><name><surname>Lopa</surname><given-names>S</given-names></name><name><surname>Wolmark</surname><given-names>N</given-names></name></person-group><year>2011</year><article-title>The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04</article-title><source>J Clin Oncol</source><volume>29</volume><supplement>(suppl 15</supplement><fpage>abstract 3503</fpage></mixed-citation></ref><ref id="bib52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sathornsumetee</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Marcello</surname><given-names>JE</given-names></name><name><surname>Herndon</surname><given-names>JE</given-names></name><name><surname>McLendon</surname><given-names>RE</given-names></name><name><surname>Desjardins</surname><given-names>A</given-names></name><name><surname>Friedman</surname><given-names>HS</given-names></name><name><surname>Dewhirst</surname><given-names>MW</given-names></name><name><surname>Vredenburgh</surname><given-names>JJ</given-names></name><name><surname>Rich</surname><given-names>JN</given-names></name></person-group><year>2008</year><article-title>Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan</article-title><source>J Clin Oncol</source><volume>26</volume><supplement>(2</supplement><fpage>271</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">18182667</pub-id></mixed-citation></ref><ref id="bib53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvakumaran</surname><given-names>M</given-names></name><name><surname>Yao</surname><given-names>KS</given-names></name><name><surname>Feldman</surname><given-names>MD</given-names></name><name><surname>O'Dwyer</surname><given-names>PJ</given-names></name></person-group><year>2008</year><article-title>Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis</article-title><source>Biochem Pharmacol</source><volume>75</volume><supplement>(3</supplement><fpage>627</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">18178171</pub-id></mixed-citation></ref><ref id="bib54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaheen</surname><given-names>RM</given-names></name><name><surname>Tseng</surname><given-names>WW</given-names></name><name><surname>Davis</surname><given-names>DW</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Reinmuth</surname><given-names>N</given-names></name><name><surname>Vellagas</surname><given-names>R</given-names></name><name><surname>Wieczorek</surname><given-names>AA</given-names></name><name><surname>Ogura</surname><given-names>Y</given-names></name><name><surname>McConkey</surname><given-names>DJ</given-names></name><name><surname>Drazan</surname><given-names>KE</given-names></name><name><surname>Bucana</surname><given-names>CD</given-names></name><name><surname>McMahon</surname><given-names>G</given-names></name><name><surname>Ellis</surname><given-names>LM</given-names></name></person-group><year>2001</year><article-title>Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms</article-title><source>Cancer Res</source><volume>61</volume><supplement>(4</supplement><fpage>1464</fpage><lpage>1468</lpage><pub-id pub-id-type="pmid">11245452</pub-id></mixed-citation></ref><ref id="bib55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>SJ</given-names></name><name><surname>Jung</surname><given-names>M</given-names></name><name><surname>Jeung</surname><given-names>HC</given-names></name><name><surname>Kim</surname><given-names>HR</given-names></name><name><surname>Rha</surname><given-names>SY</given-names></name><name><surname>Roh</surname><given-names>JK</given-names></name><name><surname>Chung</surname><given-names>HC</given-names></name><name><surname>Ahn</surname><given-names>JB</given-names></name></person-group><year>2012</year><article-title>A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy</article-title><source>Invest New Drugs</source><volume>30</volume><supplement>(4</supplement><fpage>1501</fpage><lpage>1510</lpage><pub-id pub-id-type="pmid">21567184</pub-id></mixed-citation></ref><ref id="bib56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sitohy</surname><given-names>B</given-names></name><name><surname>Nagy</surname><given-names>JA</given-names></name><name><surname>Jaminet</surname><given-names>SC</given-names></name><name><surname>Dvorak</surname><given-names>HF</given-names></name></person-group><year>2011</year><article-title>Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy</article-title><source>Cancer Res</source><volume>71</volume><supplement>(22</supplement><fpage>7021</fpage><lpage>7028</lpage><pub-id pub-id-type="pmid">21937680</pub-id></mixed-citation></ref><ref id="bib57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year>2004</year><article-title>Linear models and empirical bayes methods for assessing differential expression in microarray experiments</article-title><source>Stat Appl Genet Mol Biol</source><volume>3</volume><fpage>Article3</fpage><pub-id pub-id-type="pmid">16646809</pub-id></mixed-citation></ref><ref id="bib58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sohn</surname><given-names>WJ</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Park</surname><given-names>DG</given-names></name></person-group><year>2010</year><article-title>Change in expression of survivin caused by using oxaliplatin in HCT116 colon cancer cells</article-title><source>J Korean Soc Coloproctol</source><volume>26</volume><supplement>(4</supplement><fpage>246</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">21152225</pub-id></mixed-citation></ref><ref id="bib59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spigel</surname><given-names>DR</given-names></name><name><surname>Bendell</surname><given-names>JC</given-names></name><name><surname>McCleod</surname><given-names>M</given-names></name><name><surname>Shipley</surname><given-names>DL</given-names></name><name><surname>Arrowsmith</surname><given-names>E</given-names></name><name><surname>Barnes</surname><given-names>EK</given-names></name><name><surname>Infante</surname><given-names>JR</given-names></name><name><surname>Burris</surname><given-names>HA</given-names><suffix>III</suffix></name><name><surname>Greco</surname><given-names>FA</given-names></name><name><surname>Hainsworth</surname><given-names>JD</given-names></name></person-group><year>2012</year><article-title>Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer</article-title><source>Clin Colorectal Cancer</source><volume>11</volume><supplement>(1</supplement><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">21840771</pub-id></mixed-citation></ref><ref id="bib60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>RT</given-names></name><name><surname>Boucher</surname><given-names>Y</given-names></name><name><surname>Kozin</surname><given-names>SV</given-names></name><name><surname>Winkler</surname><given-names>F</given-names></name><name><surname>Hicklin</surname><given-names>DJ</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><year>2004</year><article-title>Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors</article-title><source>Cancer Res</source><volume>64</volume><supplement>(11</supplement><fpage>3731</fpage><lpage>3736</lpage><pub-id pub-id-type="pmid">15172975</pub-id></mixed-citation></ref><ref id="bib61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verstraete</surname><given-names>M</given-names></name><name><surname>Debucquoy</surname><given-names>A</given-names></name><name><surname>Devos</surname><given-names>E</given-names></name><name><surname>Sagaert</surname><given-names>X</given-names></name><name><surname>Penninckx</surname><given-names>F</given-names></name><name><surname>Begg</surname><given-names>A</given-names></name><name><surname>Haustermans</surname><given-names>K</given-names></name></person-group><year>2013</year><article-title>Investigation of possible endogenous hypoxia markers in colorectal cancer</article-title><source>Int J Radiat Biol</source><volume>89</volume><supplement>(1</supplement><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">22852555</pub-id></mixed-citation></ref><ref id="bib62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verstraete</surname><given-names>M</given-names></name><name><surname>Debucquoy</surname><given-names>A</given-names></name><name><surname>Sagaert</surname><given-names>X</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Haustermans</surname><given-names>K</given-names></name></person-group><year>2012</year><article-title>Anti-angiogenic therapy combined with chemoradiotherapy for patients with localized advanced rectal cancer</article-title><source>Adv Cancer Res Treatment</source><volume>2012</volume><supplement>(796042</supplement><fpage>1</fpage><lpage>30</lpage></mixed-citation></ref><ref id="bib63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voland</surname><given-names>C</given-names></name><name><surname>Bord</surname><given-names>A</given-names></name><name><surname>Peleraux</surname><given-names>A</given-names></name><name><surname>Penarier</surname><given-names>G</given-names></name><name><surname>Carriere</surname><given-names>D</given-names></name><name><surname>Galiegue</surname><given-names>S</given-names></name><name><surname>Cvitkovic</surname><given-names>E</given-names></name><name><surname>Jbilo</surname><given-names>O</given-names></name><name><surname>Casellas</surname><given-names>P</given-names></name></person-group><year>2006</year><article-title>Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells</article-title><source>Mol Cancer Ther</source><volume>5</volume><supplement>(9</supplement><fpage>2149</fpage><lpage>2157</lpage><pub-id pub-id-type="pmid">16985047</pub-id></mixed-citation></ref><ref id="bib64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Kobunai</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Matsuda</surname><given-names>K</given-names></name><name><surname>Ishihara</surname><given-names>S</given-names></name><name><surname>Nozawa</surname><given-names>K</given-names></name><name><surname>Iinuma</surname><given-names>H</given-names></name><name><surname>Ikeuchi</surname><given-names>H</given-names></name></person-group><year>2011</year><article-title>Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients</article-title><source>Dis Colon Rectum</source><volume>54</volume><supplement>(8</supplement><fpage>1026</fpage><lpage>1035</lpage><pub-id pub-id-type="pmid">21730794</pub-id></mixed-citation></ref><ref id="bib65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weisshardt</surname><given-names>P</given-names></name><name><surname>Trarbach</surname><given-names>T</given-names></name><name><surname>Durig</surname><given-names>J</given-names></name><name><surname>Paul</surname><given-names>A</given-names></name><name><surname>Reis</surname><given-names>H</given-names></name><name><surname>Tilki</surname><given-names>D</given-names></name><name><surname>Miroschnik</surname><given-names>I</given-names></name><name><surname>Ergun</surname><given-names>S</given-names></name><name><surname>Klein</surname><given-names>D</given-names></name></person-group><year>2012</year><article-title>Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab</article-title><source>Histochem Cell Biol</source><volume>137</volume><supplement>(3</supplement><fpage>391</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">22193946</pub-id></mixed-citation></ref><ref id="bib66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wildiers</surname><given-names>H</given-names></name><name><surname>Guetens</surname><given-names>G</given-names></name><name><surname>De</surname><given-names>BG</given-names></name><name><surname>Verbeken</surname><given-names>E</given-names></name><name><surname>Landuyt</surname><given-names>B</given-names></name><name><surname>Landuyt</surname><given-names>W</given-names></name><name><surname>de Bruijn</surname><given-names>EA</given-names></name><name><surname>van Oosterom</surname><given-names>AT</given-names></name></person-group><year>2003</year><article-title>Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11</article-title><source>Br J Cancer</source><volume>88</volume><supplement>(12</supplement><fpage>1979</fpage><lpage>1986</lpage><pub-id pub-id-type="pmid">12799646</pub-id></mixed-citation></ref><ref id="bib67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willett</surname><given-names>CG</given-names></name><name><surname>Boucher</surname><given-names>Y</given-names></name><name><surname>di</surname><given-names>TE</given-names></name><name><surname>Duda</surname><given-names>DG</given-names></name><name><surname>Munn</surname><given-names>LL</given-names></name><name><surname>Tong</surname><given-names>RT</given-names></name><name><surname>Chung</surname><given-names>DC</given-names></name><name><surname>Sahani</surname><given-names>DV</given-names></name><name><surname>Kalva</surname><given-names>SP</given-names></name><name><surname>Kozin</surname><given-names>SV</given-names></name><name><surname>Mino</surname><given-names>M</given-names></name><name><surname>Cohen</surname><given-names>KS</given-names></name><name><surname>Scadden</surname><given-names>DT</given-names></name><name><surname>Hartford</surname><given-names>AC</given-names></name><name><surname>Fischman</surname><given-names>AJ</given-names></name><name><surname>Clark</surname><given-names>JW</given-names></name><name><surname>Ryan</surname><given-names>DP</given-names></name><name><surname>Zhu</surname><given-names>AX</given-names></name><name><surname>Blaszkowsky</surname><given-names>LS</given-names></name><name><surname>Chen</surname><given-names>HX</given-names></name><name><surname>Shellito</surname><given-names>PC</given-names></name><name><surname>Lauwers</surname><given-names>GY</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><year>2004</year><article-title>Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer</article-title><source>Nat Med</source><volume>10</volume><supplement>(2</supplement><fpage>145</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">14745444</pub-id></mixed-citation></ref><ref id="bib68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willett</surname><given-names>CG</given-names></name><name><surname>Boucher</surname><given-names>Y</given-names></name><name><surname>Duda</surname><given-names>DG</given-names></name><name><surname>di</surname><given-names>TE</given-names></name><name><surname>Munn</surname><given-names>LL</given-names></name><name><surname>Tong</surname><given-names>RT</given-names></name><name><surname>Kozin</surname><given-names>SV</given-names></name><name><surname>Petit</surname><given-names>L</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name><name><surname>Chung</surname><given-names>DC</given-names></name><name><surname>Sahani</surname><given-names>DV</given-names></name><name><surname>Kalva</surname><given-names>SP</given-names></name><name><surname>Cohen</surname><given-names>KS</given-names></name><name><surname>Scadden</surname><given-names>DT</given-names></name><name><surname>Fischman</surname><given-names>AJ</given-names></name><name><surname>Clark</surname><given-names>JW</given-names></name><name><surname>Ryan</surname><given-names>DP</given-names></name><name><surname>Zhu</surname><given-names>AX</given-names></name><name><surname>Blaszkowsky</surname><given-names>LS</given-names></name><name><surname>Shellito</surname><given-names>PC</given-names></name><name><surname>Mino-Kenudson</surname><given-names>M</given-names></name><name><surname>Lauwers</surname><given-names>GY</given-names></name></person-group><year>2005</year><article-title>Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients</article-title><source>J Clin Oncol</source><volume>23</volume><supplement>(31</supplement><fpage>8136</fpage><lpage>8139</lpage><pub-id pub-id-type="pmid">16258121</pub-id></mixed-citation></ref><ref id="bib69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willett</surname><given-names>CG</given-names></name><name><surname>Duda</surname><given-names>DG</given-names></name><name><surname>Ancukiewicz</surname><given-names>M</given-names></name><name><surname>Shah</surname><given-names>M</given-names></name><name><surname>Czito</surname><given-names>BG</given-names></name><name><surname>Bentley</surname><given-names>R</given-names></name><name><surname>Poleski</surname><given-names>M</given-names></name><name><surname>Fujita</surname><given-names>H</given-names></name><name><surname>Lauwers</surname><given-names>GY</given-names></name><name><surname>Carroll</surname><given-names>M</given-names></name><name><surname>Tyler</surname><given-names>D</given-names></name><name><surname>Mantyh</surname><given-names>C</given-names></name><name><surname>Shellito</surname><given-names>P</given-names></name><name><surname>Chung</surname><given-names>DC</given-names></name><name><surname>Clark</surname><given-names>JW</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><year>2010</year><article-title>A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer</article-title><source>Oncologist</source><volume>15</volume><supplement>(8</supplement><fpage>845</fpage><lpage>851</lpage><pub-id pub-id-type="pmid">20667969</pub-id></mixed-citation></ref><ref id="bib70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willett</surname><given-names>CG</given-names></name><name><surname>Duda</surname><given-names>DG</given-names></name><name><surname>di</surname><given-names>TE</given-names></name><name><surname>Boucher</surname><given-names>Y</given-names></name><name><surname>Ancukiewicz</surname><given-names>M</given-names></name><name><surname>Sahani</surname><given-names>DV</given-names></name><name><surname>Lahdenranta</surname><given-names>J</given-names></name><name><surname>Chung</surname><given-names>DC</given-names></name><name><surname>Fischman</surname><given-names>AJ</given-names></name><name><surname>Lauwers</surname><given-names>GY</given-names></name><name><surname>Shellito</surname><given-names>P</given-names></name><name><surname>Czito</surname><given-names>BG</given-names></name><name><surname>Wong</surname><given-names>TZ</given-names></name><name><surname>Paulson</surname><given-names>E</given-names></name><name><surname>Poleski</surname><given-names>M</given-names></name><name><surname>Vujaskovic</surname><given-names>Z</given-names></name><name><surname>Bentley</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>HX</given-names></name><name><surname>Clark</surname><given-names>JW</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><year>2009</year><article-title></article-title><source>J Clin Oncol</source><volume>27</volume><supplement>(18</supplement><fpage>3020</fpage><lpage>3026</lpage><pub-id pub-id-type="pmid">19470921</pub-id></mixed-citation></ref><ref id="bib71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>PM</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Azuma</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>MM</given-names></name><name><surname>Danenberg</surname><given-names>KD</given-names></name><name><surname>Lebwohl</surname><given-names>D</given-names></name><name><surname>Sherrod</surname><given-names>A</given-names></name><name><surname>Ladner</surname><given-names>RD</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Danenberg</surname><given-names>PV</given-names></name><name><surname>Trarbach</surname><given-names>T</given-names></name><name><surname>Folprecht</surname><given-names>G</given-names></name><name><surname>Meinhardt</surname><given-names>G</given-names></name><name><surname>Lenz</surname><given-names>HJ</given-names></name></person-group><year>2012</year><article-title>Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib)</article-title><source>Pharmacogenomics J</source><volume>13</volume><supplement>(5</supplement><fpage>410</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">22664478</pub-id></mixed-citation></ref><ref id="bib72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winkler</surname><given-names>F</given-names></name><name><surname>Kozin</surname><given-names>SV</given-names></name><name><surname>Tong</surname><given-names>RT</given-names></name><name><surname>Chae</surname><given-names>SS</given-names></name><name><surname>Booth</surname><given-names>MF</given-names></name><name><surname>Garkavtsev</surname><given-names>I</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Hicklin</surname><given-names>DJ</given-names></name><name><surname>Fukumura</surname><given-names>D</given-names></name><name><surname>di</surname><given-names>TE</given-names></name><name><surname>Munn</surname><given-names>LL</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><year>2004</year><article-title>Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases</article-title><source>Cancer Cell</source><volume>6</volume><supplement>(6</supplement><fpage>553</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">15607960</pub-id></mixed-citation></ref><ref id="bib73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>SX</given-names></name><name><surname>Steinberg</surname><given-names>SM</given-names></name><name><surname>Nguyen</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>TD</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><name><surname>Swain</surname><given-names>SM</given-names></name></person-group><year>2008</year><article-title>Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer</article-title><source>Clin Cancer Res</source><volume>14</volume><supplement>(18</supplement><fpage>5893</fpage><lpage>5899</lpage><pub-id pub-id-type="pmid">18794102</pub-id></mixed-citation></ref><ref id="bib74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>MY</given-names></name><name><surname>Xiao</surname><given-names>ZX</given-names></name><name><surname>Peng</surname><given-names>JP</given-names></name><name><surname>Dong</surname><given-names>Q</given-names></name></person-group><year>2003</year><article-title>Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma</article-title><source>World J Gastroenterol</source><volume>9</volume><supplement>(6</supplement><fpage>1227</fpage><lpage>1230</lpage><pub-id pub-id-type="pmid">12800229</pub-id></mixed-citation></ref></ref-list><sec sec-type="supplementary-material" id="sup1"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="xob1"><label>Supplementary Figure 1</label><media xlink:href="bjc201593x1.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob2"><label>Supplementary Figure 2</label><media xlink:href="bjc201593x2.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob3"><label>Supplementary Figure 3</label><media xlink:href="bjc201593x3.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob4"><label>Supplementary Figure 4</label><media xlink:href="bjc201593x4.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob5"><label>Supplementary Table 1</label><media xlink:href="bjc201593x5.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob6"><label>Supplementary Table 2</label><media xlink:href="bjc201593x6.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob7"><label>Supplementary Table 3</label><media xlink:href="bjc201593x7.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob8"><label>Supplementary Table 4</label><media xlink:href="bjc201593x8.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob9"><label>Supplementary Table 5</label><media xlink:href="bjc201593x9.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob10"><label>Supplementary Materials and Methods</label><media xlink:href="bjc201593x10.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p><bold>Inclusion and selection process of the samples used for translational research.</bold> After clinical and technical selection of the 59 patients included, 50 and 47 patients, respectively, at T0 and T1 were evaluated for tissue markers, 20 patients for gene expression levels and 59 patients for blood markers. Abbreviations: FFPE=formalin-fixed paraffin embedded; FUP=follow-up; H&amp;E=haematoxylin–eosin; M=healthy mucosa; NR=non-responder; QC=quality control; R=responder; T0=tumour taken at baseline; T1=tumour taken after one dose bevacizumab.</p></caption><graphic xlink:href="bjc201593f1"></graphic></fig><fig id="fig2"><label>Figure 2</label><caption><p><bold>Changes in circulating markers during bevacizumab treatment.</bold> Box plots of circulating levels at T0 and T2 measured by ELISA in responding <italic>vs</italic> non-responding patients. (<bold>A, B</bold>) Changes in PDGF-AA and (<bold>C, D</bold>) PDGF-BB levels. Each plot represents the 25th and 75th percentile. The square inside the box indicates the median, and the whiskers indicate the minimum and maximum values. <italic>P</italic>-values: Mann–Whitney <italic>U</italic>-test. Abbreviations: pCR=pathological complete response; T0=baseline; T2=after two doses bevacizumab.</p></caption><graphic xlink:href="bjc201593f2"></graphic></fig><fig id="fig3"><label>Figure 3</label><caption><p><bold>Changes in tissue markers during bevacizumab treatment.</bold> Box plots of expression levels at T0 and T1 measured by IHC in responding <italic>vs</italic> non-responding patients. (<bold>A</bold>, <bold>B</bold>) Changes in percentage of pericyte-covered blood vessels (BV), (<bold>C</bold>, <bold>D</bold>) MVD and (<bold>E</bold>, <bold>F</bold>) tumour hypoxia (CA-IX). Each plot represents the 25th and 75th percentile. The square inside the box indicates the median, and the whiskers indicate the minimum and maximum values. Indicated <italic>P</italic>-values by Mann–Whitney <italic>U</italic>-test. Abbreviations: pCR=pathological complete response; T0=baseline; T1=after one dose bevacizumab.</p></caption><graphic xlink:href="bjc201593f3"></graphic></fig><fig id="fig4"><label>Figure 4</label><caption><p><bold>Correlation of markers with treatment response.</bold> Box plots of expression levels for patients with and without pCR. (<bold>A</bold>) Tumoral <italic>PDGFA</italic> expression, (<bold>B</bold>) pericyte coverage of blood vessels (BV) and (<bold>C</bold>) CA-IX expression after one dose of bevacizumab (T1). (<bold>D</bold>) Circulating PDGF-BB after two doses of bevacizumab (T2). Each plot represents the 25th and 75th percentile. The square inside the box indicates the median and the whiskers indicate the minimum and maximum values. <italic>P</italic>-values: Mann–Whitney <italic>U</italic>-test. Abbreviation: pCR=pathological complete response.</p></caption><graphic xlink:href="bjc201593f4"></graphic></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Patient characteristics and pathological response.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th align="center" valign="top" charoff="50"><bold>Arm A (</bold><italic><bold>n</bold></italic><bold>=31), no. of patients (53%)</bold></th><th align="center" valign="top" charoff="50"><bold>Arm B (</bold><italic><bold>n</bold></italic><bold>=28), no. of patients (47%)</bold></th></tr></thead><tbody valign="top"><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>Age</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Mean</td><td align="center" valign="top" charoff="50">59</td><td align="center" valign="top" charoff="50">60</td></tr><tr><td align="left" valign="top" charoff="50">Range</td><td align="center" valign="top" charoff="50">26–77</td><td align="center" valign="top" charoff="50">45–78</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>Gender</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">Male</td><td align="char" valign="top" char="(" charoff="50">9 (29%)</td><td align="char" valign="top" char="(" charoff="50">8 (29%)</td></tr><tr><td align="left" valign="top" charoff="50">Female</td><td align="char" valign="top" char="(" charoff="50">22 (71%)</td><td align="char" valign="top" char="(" charoff="50">20 (71%)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>Tumour stage</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">cT2</td><td align="char" valign="top" char="(" charoff="50">2 (6%)</td><td align="char" valign="top" char="(" charoff="50">1 (4%)</td></tr><tr><td align="left" valign="top" charoff="50">cT3</td><td align="char" valign="top" char="(" charoff="50">22 (71%)</td><td align="char" valign="top" char="(" charoff="50">20 (71%)</td></tr><tr><td align="left" valign="top" charoff="50">cT4</td><td align="char" valign="top" char="(" charoff="50">7 (23%)</td><td align="char" valign="top" char="(" charoff="50">7 (25%)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>Nodal stage</bold><xref ref-type="fn" rid="t1-fn2">a</xref><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">cN0</td><td align="char" valign="top" char="(" charoff="50">5 (16%)</td><td align="char" valign="top" char="(" charoff="50">2 (7%)</td></tr><tr><td align="left" valign="top" charoff="50">cN1</td><td align="char" valign="top" char="(" charoff="50">11 (36%)</td><td align="char" valign="top" char="(" charoff="50">9 (32%)</td></tr><tr><td align="left" valign="top" charoff="50">cN2</td><td align="char" valign="top" char="(" charoff="50">14 (45%)</td><td align="char" valign="top" char="(" charoff="50">16 (57%)</td></tr><tr><td align="left" valign="top" charoff="50">pCR</td><td align="char" valign="top" char="(" charoff="50">11 (36%)<xref ref-type="fn" rid="t1-fn3">b</xref></td><td align="char" valign="top" char="(" charoff="50">3 (11%)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><bold>Dworak</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">1 (3%)</td><td align="char" valign="top" char="(" charoff="50">1 (4%)</td></tr><tr><td align="left" valign="top" charoff="50">1</td><td align="char" valign="top" char="(" charoff="50">3 (10%)</td><td align="char" valign="top" char="(" charoff="50">5 (18%)</td></tr><tr><td align="left" valign="top" charoff="50">2</td><td align="char" valign="top" char="(" charoff="50">4 (13%)</td><td align="char" valign="top" char="(" charoff="50">10 (36%)</td></tr><tr><td align="left" valign="top" charoff="50">3</td><td align="char" valign="top" char="(" charoff="50">11 (36%)</td><td align="char" valign="top" char="(" charoff="50">9 (32%)</td></tr><tr><td align="left" valign="top" charoff="50">4</td><td align="char" valign="top" char="(" charoff="50">11(36%)<xref ref-type="fn" rid="t1-fn3">b</xref></td><td align="char" valign="top" char="(" charoff="50">3 (11%)</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviation: pCR=pathological complete response.</p></fn><fn id="t1-fn2"><label>a</label><p>Nodal stage of two patients not known.</p></fn><fn id="t1-fn3"><label>b</label><p>One patient lost to follow-up.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2"><label>Table 2</label><caption><title>Alterations in biological processes in response to bevacizumab in responding patients</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Term</bold></th><th align="center" valign="top" charoff="50"><bold>Genes</bold></th><th align="center" valign="top" charoff="50"><italic><bold>P</bold></italic><bold>-value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Angiogenesis</td><td align="center" valign="top" charoff="50"><italic>FLT1, IL-8, PDGFA, CTGF, ROBO4, ENPEP, TSP-1, ANGPT2, CYR61</italic></td><td align="center" valign="top" charoff="50">0.0002</td></tr><tr><td align="left" valign="top" charoff="50">Blood vessel morphogenesis</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50">0.0028</td></tr><tr><td align="left" valign="top" charoff="50">Blood vessel development</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50">0.0083</td></tr><tr><td align="left" valign="top" charoff="50">vasculature development</td><td align="center" valign="top" charoff="50"> </td><td align="center" valign="top" charoff="50">0.0099</td></tr></tbody></table></table-wrap><table-wrap id="tbl3"><label>Table 3</label><caption><title>Unique biological processes in patients with and without a pathological complete response at baseline</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="left"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Term</bold></th><th align="left" valign="top" charoff="50"> </th><th align="center" valign="top" charoff="50"><bold>Gene count</bold></th><th align="center" valign="top" charoff="50"><italic><bold>P</bold></italic><bold>-value</bold></th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" charoff="50"><bold>Responders</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">GO:0001944</td><td align="left" valign="top" charoff="50">Vasculature development</td><td align="center" valign="top" charoff="50">61</td><td align="center" valign="top" charoff="50">0.00016</td></tr><tr><td align="left" valign="top" charoff="50">GO:0006928</td><td align="left" valign="top" charoff="50">Cell motion</td><td align="center" valign="top" charoff="50">96</td><td align="center" valign="top" charoff="50">0.00034</td></tr><tr><td align="left" valign="top" charoff="50">GO:0001568</td><td align="left" valign="top" charoff="50">Blood vessel development</td><td align="center" valign="top" charoff="50">59</td><td align="center" valign="top" charoff="50">0.00039</td></tr><tr><td align="left" valign="top" charoff="50">GO:0016477</td><td align="left" valign="top" charoff="50">Cell migration</td><td align="center" valign="top" charoff="50">63</td><td align="center" valign="top" charoff="50">0.00107</td></tr><tr><td align="left" valign="top" charoff="50">GO:0051325</td><td align="left" valign="top" charoff="50">Interphase</td><td align="center" valign="top" charoff="50">32</td><td align="center" valign="top" charoff="50">0.00353</td></tr><tr><td align="left" valign="top" charoff="50">GO:0006259</td><td align="left" valign="top" charoff="50">DNA metabolic process</td><td align="center" valign="top" charoff="50">97</td><td align="center" valign="top" charoff="50">0.00372</td></tr><tr><td align="left" valign="top" charoff="50">GO:0007626</td><td align="left" valign="top" charoff="50">Locomotory behaviour</td><td align="center" valign="top" charoff="50">61</td><td align="center" valign="top" charoff="50">0.00412</td></tr><tr><td align="left" valign="top" charoff="50">GO:0008285</td><td align="left" valign="top" charoff="50">Negative regulation of cell proliferation</td><td align="center" valign="top" charoff="50">74</td><td align="center" valign="top" charoff="50">0.00708</td></tr><tr><td align="left" valign="top" charoff="50">GO:0051783</td><td align="left" valign="top" charoff="50">Regulation of nuclear division</td><td align="center" valign="top" charoff="50">21</td><td align="center" valign="top" charoff="50">0.01059</td></tr><tr><td align="left" valign="top" charoff="50">GO:0007088</td><td align="left" valign="top" charoff="50">Regulation of mitosis</td><td align="center" valign="top" charoff="50">21</td><td align="center" valign="top" charoff="50">0.01059</td></tr><tr><td align="left" valign="top" charoff="50">GO:0051674</td><td align="left" valign="top" charoff="50">Localisation of cell</td><td align="center" valign="top" charoff="50">65</td><td align="center" valign="top" charoff="50">0.01078</td></tr><tr><td align="left" valign="top" charoff="50">GO:0048870</td><td align="left" valign="top" charoff="50">Cell motility</td><td align="center" valign="top" charoff="50">65</td><td align="center" valign="top" charoff="50">0.01078</td></tr><tr><td align="left" valign="top" charoff="50">GO:0048514</td><td align="left" valign="top" charoff="50">Blood vessel morphogenesis</td><td align="center" valign="top" charoff="50">49</td><td align="center" valign="top" charoff="50">0.01621</td></tr><tr><td align="left" valign="top" charoff="50">GO:0051329</td><td align="left" valign="top" charoff="50">Interphase of mitotic cell cycle</td><td align="center" valign="top" charoff="50">30</td><td align="center" valign="top" charoff="50">0.01822</td></tr><tr><td align="left" valign="top" charoff="50">GO:0007051</td><td align="left" valign="top" charoff="50">Spindle organisation</td><td align="center" valign="top" charoff="50">18</td><td align="center" valign="top" charoff="50">0.02463</td></tr><tr><td align="left" valign="top" charoff="50">GO:0042060</td><td align="left" valign="top" charoff="50">Wound healing</td><td align="center" valign="top" charoff="50">45</td><td align="center" valign="top" charoff="50">0.02858</td></tr><tr><td align="left" valign="top" charoff="50">GO:0001501</td><td align="left" valign="top" charoff="50">Skeletal system development</td><td align="center" valign="top" charoff="50">65</td><td align="center" valign="top" charoff="50">0.03977</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><bold>Non-responders</bold><hr></hr></td></tr><tr><td align="left" valign="top" charoff="50">GO:0046942</td><td align="left" valign="top" charoff="50">Carboxylic acid transport</td><td align="center" valign="top" charoff="50">39</td><td align="center" valign="top" charoff="50">0.00325</td></tr><tr><td align="left" valign="top" charoff="50">GO:0015849</td><td align="left" valign="top" charoff="50">Organic acid transport</td><td align="center" valign="top" charoff="50">39</td><td align="center" valign="top" charoff="50">0.00389</td></tr><tr><td align="left" valign="top" charoff="50">GO:0060348</td><td align="left" valign="top" charoff="50">Bone development</td><td align="center" valign="top" charoff="50">34</td><td align="center" valign="top" charoff="50">0.00695</td></tr><tr><td align="left" valign="top" charoff="50">GO:0007586</td><td align="left" valign="top" charoff="50">Digestion</td><td align="center" valign="top" charoff="50">28</td><td align="center" valign="top" charoff="50">0.00741</td></tr><tr><td align="left" valign="top" charoff="50">GO:0031667</td><td align="left" valign="top" charoff="50">Response to nutrient levels</td><td align="center" valign="top" charoff="50">46</td><td align="center" valign="top" charoff="50">0.01340</td></tr><tr><td align="left" valign="top" charoff="50">GO:0007584</td><td align="left" valign="top" charoff="50">Response to nutrient</td><td align="center" valign="top" charoff="50">36</td><td align="center" valign="top" charoff="50">0.01966</td></tr></tbody></table></table-wrap><table-wrap id="tbl4"><label>Table 4</label><caption><title>Alterations in response to one dose of bevacizumab</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Parameter</bold></th><th align="center" valign="top" charoff="50"><bold>Willett phase I</bold></th><th align="center" valign="top" charoff="50"><bold>Willett phase II</bold></th><th align="center" valign="top" charoff="50"><bold>AXEBeam study</bold></th><th align="center" valign="top" charoff="50"><bold>Willet</bold>
<italic><bold>vs</bold></italic>
<bold>AXEBeam</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Blood flow</td><td align="center" valign="top" charoff="50">Decrease<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="center" valign="top" charoff="50">Decrease<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">Blood volume</td><td align="center" valign="top" charoff="50">Decrease<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="center" valign="top" charoff="50">Decrease</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">PS product</td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50">Decrease<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">FDG uptake</td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">IFP</td><td align="center" valign="top" charoff="50">Decrease<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="center" valign="top" charoff="50">Decrease<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">MVD</td><td align="center" valign="top" charoff="50">Decrease<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">Decrease<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="center" valign="top" charoff="50"><bold>=</bold></td></tr><tr><td align="left" valign="top" charoff="50">% α-SMA coverage</td><td align="center" valign="top" charoff="50">Increase</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">Decrease<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="center" valign="top" charoff="50"><bold>≠</bold></td></tr><tr><td align="left" valign="top" charoff="50">% Ang-2-positive BV</td><td align="center" valign="top" charoff="50">Decrease<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">Tumour cell proliferation</td><td align="center" valign="top" charoff="50">Increase</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">Decrease<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="center" valign="top" charoff="50"><bold>≠</bold></td></tr><tr><td align="left" valign="top" charoff="50">Tumour cell apoptosis</td><td align="center" valign="top" charoff="50">Increase<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50"><bold>≠</bold></td></tr><tr><td align="left" valign="top" charoff="50">CA-IX expression</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">Increase</td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">CECs</td><td align="center" valign="top" charoff="50">Decrease<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">CPCs</td><td align="center" valign="top" charoff="50">Decrease<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">Circulating VEGF</td><td align="center" valign="top" charoff="50">Increase<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="center" valign="top" charoff="50">Increase<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="center" valign="top" charoff="50">Increase<xref ref-type="fn" rid="t4-fn2">a</xref><sup>,</sup><xref ref-type="fn" rid="t4-fn3">b</xref></td><td align="center" valign="top" charoff="50"><bold>=</bold></td></tr><tr><td align="left" valign="top" charoff="50">Circulating PlGF</td><td align="center" valign="top" charoff="50">Increase<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="center" valign="top" charoff="50">Increase<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="center" valign="top" charoff="50">No effect<xref ref-type="fn" rid="t4-fn4">c</xref></td><td align="center" valign="top" charoff="50"><bold>≠</bold></td></tr><tr><td align="left" valign="top" charoff="50">Circulating sVEGFR1</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50">No effect<xref ref-type="fn" rid="t4-fn4">c</xref></td><td align="center" valign="top" charoff="50"><bold>=</bold></td></tr><tr><td align="left" valign="top" charoff="50">Circulating sVEGFR2</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50">No effect<xref ref-type="fn" rid="t4-fn4">c</xref></td><td align="center" valign="top" charoff="50"><bold>=</bold></td></tr><tr><td align="left" valign="top" charoff="50">Circulating IL-6</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">Increase<xref ref-type="fn" rid="t4-fn2">a</xref></td><td align="center" valign="top" charoff="50">No effect<xref ref-type="fn" rid="t4-fn4">c</xref></td><td align="center" valign="top" charoff="50"><bold>≠</bold></td></tr><tr><td align="left" valign="top" charoff="50">Circulating IL-8</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50">Decrease</td><td align="center" valign="top" charoff="50"><bold>≠</bold></td></tr><tr><td align="left" valign="top" charoff="50">Circulating IL-1<italic>β</italic></td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">Circulating PDGF-AA</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">Circulating PDGF-BB</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">Circulating TSP-1</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">Circulating TSP-2</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect<xref ref-type="fn" rid="t4-fn3">b</xref></td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">Circulating Ang-2</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">Decrease</td><td align="center" valign="top" charoff="50"></td></tr><tr><td align="left" valign="top" charoff="50">Circulating Ang-1</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect<xref ref-type="fn" rid="t4-fn3">b</xref></td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">Circulating Cyr61</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">Circulating FGFa</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect<xref ref-type="fn" rid="t4-fn4">c</xref></td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">Circulating FGFb</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50">No effect<xref ref-type="fn" rid="t4-fn4">c</xref></td><td align="center" valign="top" charoff="50"><bold>=</bold></td></tr><tr><td align="left" valign="top" charoff="50">Circulating osteopontin</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect<xref ref-type="fn" rid="t4-fn4">c</xref></td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">Circulating sICAM</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect<xref ref-type="fn" rid="t4-fn4">c</xref></td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">Circulating VEGF-D</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect<xref ref-type="fn" rid="t4-fn3">b</xref></td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">Circulating SDF1α</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">Circulating TNF-α</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">Circulating GM-CSF</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">Circulating CEA</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">Gene expression</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">cfr. Table e3</td><td align="center" valign="top" charoff="50">?</td></tr><tr><td align="left" valign="top" charoff="50">Tumour regression</td><td align="center" valign="top" charoff="50">1/6 Patients</td><td align="center" valign="top" charoff="50">No effect</td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">?</td></tr></tbody></table><table-wrap-foot><fn id="t4-fn1"><p>Abbreviations: Ang=angiopoietin; BV=blood vessels; CEA=carcinoembryonic antigen; CECs=circulating endothelial cells; CPCs=circulating progenitor cells; FGF=fibroblast growth factor; IFP=interstitial fluid pressure; GM-CSF=granulocyte macrophage colony-stimulating factor; IL=interleukin; MVD=microvessel density; NA=Not analysed; PDGF=platelet-derived growth factor; PlGF=placental growth factor; PS=permeability surface area product; SDF=stromal cell-derived factor; TNF=tumour necrosis factor; TSP=trombospondin; VEGF=vascular endothelial growth factor.</p></fn><fn id="t4-fn2"><label>a</label><p>Significant change <italic>P</italic>&lt;0.05.</p></fn><fn id="t4-fn3"><label>b</label><p>32 Patients were analysed.</p></fn><fn id="t4-fn4"><label>c</label><p>14 Patients were analysed.</p></fn></table-wrap-foot></table-wrap></floats-group></article>